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Staphylococcus aureus (S. aureus) is a leading cause of community- and healthcare-
associated infections and has a propensity to form biofilms. Biofilm infections are 
recalcitrant to host immune-mediated clearance as well as antibiotics, making them 
exceptionally difficult to eradicate. The biofilm environment has been shown to skew the 
host immune response towards an anti-inflammatory phenotype, characterized by 
alternatively activated macrophages, recruitment of myeloid-derived suppressor cells 
(MDSCs), and minimal neutrophil and T cell infiltrates. Our laboratory has attempted to 
redirect the host immune response towards one that would favor bacterial clearance by 
employing strategies to augment pro-inflammatory mechanisms. One such approach 
was to utilize lipopolysaccharide (LPS), which was expected to promote pro-
inflammatory activation of peripheral immune cells infiltrating the biofilm and subsequent 
clearance of infection. This theory was partially correct, as pro-inflammatory cytokines in 
the serum were significantly increased, and peripheral immune cells in the blood were 
more effective at killing S. aureus ex vivo following LPS treatment; however biofilm 
infection was exacerbated. Specifically, bacterial titers increased nearly 2-log with 
administration of LPS, and although infiltration of Ly6G+Ly6C+ MDSCs was decreased, a 
new population of Ly6GintLy6C+ cells appeared. Additionally, both Ly6G+Ly6C+ and 
Ly6GintLy6C+ populations were more suppressive with LPS treatment, partially 
explaining the expansion of S. aureus biofilm burdens. This study highlights the resilient 
nature of S. aureus biofilm infections to influence the immune response, particularly 
through MDSCs, even in the face of a strong pro-inflammatory stimulus. Gaining a better 
understanding of the mechanisms that cause this ineffective host immune response to 

















Staphylococcus aureus and biofilm infection 
Staphylococcus aureus infections and clinical significance 
 Staphylococcus aureus (S. aureus) is a gram-positive bacterium that has 
remained a versatile and dangerous pathogen ever since its discovery in the 1880’s [1]. 
The skin and nasal mucosa of approximately 30% of the world population are colonized 
with methicillin-sensitive S. aureus (MSSA), and approximately 1-2% are colonized with 
methicillin-resistant strains, known as MRSA, while prevalence among healthcare 
workers is closer to 5% [2-6] . According to a 2014 report from the CDC, over 80,000 
invasive MRSA infections and more than 10,000 related deaths occur every year in the 
United States alone. The pathogen is responsible for a wide range of diseases, including 
superficial skin and soft tissue infections, respiratory infections, food poisoning, bacterial 
pneumonia, and sepsis [5]. The microorganism can colonize an individual for a long 
period with no apparent repercussions, until a breach of the skin or mucosal barrier 
introduces the possibility of infection. It is not well understood what determines whether 
an infection is contained or disseminates, and more research is needed to understand 
the complex interplay between S. aureus virulence determinants and host defense 
mechanisms. 
S. aureus biofilms and prosthetic joint infections 
 An important virulence determinant of S. aureus is its ability to form a biofilm on 
biological and artificial surfaces [7, 8]. A biofilm is a community of surface-associated 
bacteria that is enclosed in a complex matrix composed of proteins, polysaccharides, 
and eDNA [7-13]. Staphylococci are among the most frequent cause of biofilm-
associated infections, and biofilm formation allows the bacteria to circumvent antibiotic- 
and immune-mediated clearance to establish persistent infections [8, 14, 15].  
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Biofilm development can be described as a continuous cycle with three distinct 
stages. The process begins by initial attachment of bacterial cells to biotic or abiotic 
surfaces, such as a heart valve or orthopedic device. Next, accumulation of bacteria and 
extracellular matrix (ECM) occurs as the biofilm matures. During the final stage, cells 
begin to detach from the biofilm proper, facilitating biofilm dispersal and possible 
reattachment at another site, continuing the cycle [8, 14, 16, 17]. Although we are 
beginning to understand some of the mechanisms whereby staphylococcal biofilms 
evade immune attack [12, 18-22], it is likely that additional pathways remain to be 
identified. 
The biofilm mode of growth often includes dampening of protein and cell wall 
biosynthesis, thereby allowing the pathogen to avoid eradication by antibiotics that target 
actively growing cells [23-25]. Combined with its capacity for immune evasion and 
antibiotic resistance, staphylococcal biofilms also produce numerous virulence factors 
that target immune cells and damage host tissues. Only a small number of bacteria are 
needed to establish medical device-related infections, and their recalcitrance to 
antibiotics makes biofilms difficult to treat [13, 26]. In most cases, the contaminated 
device must be removed with an ensuing lengthy antibiotic regimen until the site is 
considered sterile, whereupon a new device is placed. This sequence of events prolongs 
recovery time and is an economic burden for the patient [27, 28]. Indeed, approximately 
$1.8 billion is spent annually in the US for the treatment and clinical management of 
orthopedic implant-related infections [29, 30]. The cost will continue to rise, as it is 
projected that from 2005 to 2030, the number of total hip arthroplasty procedures will 
increase 174%, and total knee arthroplasties by 673% [31, 32]. When considering the 
increasing number of device-related procedures [32-34], nosocomial infections that can 
accompany these procedures in the hospital setting, and the continued emergence of 
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community-acquired S. aureus infections [35], a better understanding of the mechanisms 
that staphylococcal biofilms utilize to evade host immunity is one necessary step 
towards eradicating these chronic and debilitating infections. 
Mouse model of orthopedic implant-associated biofilm infection 
 Our laboratory has utilized a mouse model of orthopedic implant-associated 
infection for the study of S. aureus biofilm infections and host-pathogen interactions [12, 
36-39]. The proximity of the chronic biofilm infection and bone marrow make this model 
uniquely suited for the study of the host immune response to the invading pathogen. 
This model is typified by an early pro-inflammatory response resulting in the upregulation 
of IL-12p70, TNF-α, IL-1β, IL-6, and IL-17 [9], but is closely followed by a chronic anti-
inflammatory response. MDSCs are recruited to the site indirectly by IL-12, most likely 
by inducing the expression of a chemokine(s) with actions on MDSCs, which have yet to 
be identified [40]. These cells also increase anti-inflammatory signaling via IL-10 
inhibiting immune-mediated clearance, and the biofilm persists [38, 41]. This model has 
allowed for a clearer interpretation of the mechanisms governing the innate immune 
response to S. aureus biofilms, but much more information remains to be elucidated in 
order to successfully treat these devastating infections. 
Innate immune recognition and evasion of staphylococci 
Innate immune cells recognize conserved pathogen-associated molecular 
patterns (PAMPs) expressed by microorganisms via pattern recognition receptors 
(PRRs) [42]. Toll-like receptors (TLRs) are a subset of PRRs that participate in innate 
immunity by recognizing common bacterial motifs and primarily trigger nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) activation [43-45]. These 
receptors are among the best-described PRRs in mammals, of which thirteen have been 
identified in humans, and ten in mice [42, 46]. TLR signaling, with the exception of TLR3, 
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recruits the adaptor molecule MyD88 to the intracellular TIR domain of the receptor and 
elicits a signaling cascade that induces NF-κB activation, leading to the transcription of 
various cytokines, chemokines, co-stimulatory molecules, and antimicrobial peptides 
involved in defense responses [47].  
NF-κB regulates the expression of several genes associated with proliferation, 
differentiation, and cell death, as well as innate and adaptive immune responses [48], 
and is often targeted by microbes to subvert immune-mediated clearance [49]. As a 
demonstration of its importance during biofilm-mediated S. aureus infections, MyD88 
knockout (KO) mice displayed significant increases in bacterial burdens and 
dissemination, fibrosis, and decreased expression of several pro-inflammatory mediators 
[19]. This prevented the establishment of a robust immune response needed to clear the 
infection, and created an environment disadvantageous to the host, as evidenced by the 
presence of macrophages that were polarized to an anti-inflammatory phenotype in a 
model of catheter-associated biofilm infection compared to wild type (WT) animals [19]. 
Other receptors utilize MyD88, including IL-1R and IL-18R [50], although it remains 
unclear whether one receptor is dominant, or if multiple pathways interact synergistically. 
In agreement with a role for MyD88-dependent signaling in controlling early S. aureus 
biofilm growth, a recent study demonstrated similar increases in bacterial burdens in IL-
1R KO mice in a S. aureus orthopedic implant infection model [51]. Additionally, IL-1β 
has been revealed to play a role in controlling early bacterial burdens during biofilm 
infections. IL-1β KO mice displayed enhanced biofilm formation and decreased 
neutrophil recruitment [38]. Collectively, these studies reveal a role for innate immune 
mechanisms in early biofilm containment; however, it is clear that this response is not 
sufficient to clear biofilm infections due to their persistence in both animal models and 
humans. Indeed, both the MyD88 and IL-1R KO biofilm models only revealed enhanced 
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bacterial burdens during the early stages of infection, which dissipated over time. Upon 
colonization, bacteria maintain a planktonic lifestyle that elicits more traditional pro-
inflammatory responses until biofilm formation has ensued, whereupon the host immune 
response transitions to an anti-inflammatory milieu dominated by the recruitment of 
myeloid-derived suppressor cells (MDSCs) and anti-inflammatory macrophages, which 
will be described in more detail below. 
In terms of planktonic staphylococci, TLR2-mediated recognition of lipoproteins 
[52-55], polysaccharide intercellular adhesion (PIA), and phenol-soluble modulins 
(PSMs) [56, 57] leads to the production of numerous pro-inflammatory cytokines, 
including TNFα and IL-1β, important regulators of the immune response. Although there 
has been some controversy regarding peptidoglycan (PGN) as a TLR2 ligand due to 
concerns of reagent purity, recent studies using ultra-pure preparations have confirmed 
its ability to engage the receptor [58]. Other staphylococcal PAMPs, such as lipoteichoic 
acid (LTA), are not inherently pro-inflammatory; however, they can augment immune 
activation in the presence of other PAMPs [59]. TLR9 is an intracellular PRR that 
recognizes unmethylated CpG DNA motifs, which occur more frequently in the bacterial 
genome compared to mammalian DNA [60]. Despite harboring several potent TLR 
ligands, staphylococcal biofilms have been reported to evade TLR recognition [12, 38] 
(Fig. 1.1.). Remarkably, TLR9 evasion is a hallmark of S. aureus biofilms [12] despite 
extracellular DNA (eDNA) representing a major biofilm component [61], which may be 
explained by leukocyte inaccessibility to eDNA when shielded by the matrix. 
Staphylococcal biofilms are known to evade TLR2 recognition, as evidenced by patients 
with mutations inactivating TLR2 have no increased incidence of post-arthroplasty S. 
aureus infection [62]. It has been shown that TLR2 activation is inhibited by 
staphylococcal superantigen-like protein 3 (SSL3), preventing neutrophil and monocyte 
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activation, as well as IL-8 production [63, 64]. Although TLR2 and TLR9 are essential for 
S. aureus recognition during planktonic infection [12], the biofilm form of growth 
successfully evades these extracellular sensing mechanisms.  
Besides surface-associated PRRs, phagocytes are equipped with nucleotide-
binding oligomerization domain (NOD) receptors that detect intracellular 
microorganisms, providing a second line of defense to ensure immune activation [65-68]. 
NOD1 is triggered by meso-diaminopimelic acid [69, 70] while NOD2 is activated by 
muramyl dipeptide (MDP) [65]. Both NOD1 and NOD2 recognize PGN degradation 
products; however, staphylococcal PGN does not contain meso-diaminopimelic acid, but 
it does contain MDP, making immune cells rely solely on NOD2 for sensing. MDP must 
reach the host cytosol to stimulate NOD2 and eventual NF-κB activation, which may not 
occur frequently the context of a biofilm infection, due to the complex matrix preventing 
immune cell infiltration [71, 72]. Aside from the molecules produced by staphylococci to 
actively block immune recognition, TLR2 and TLR9 evasion by biofilms may be further 
explained by ligand inaccessibility [11, 12]. For example, few planktonic bacteria are 
exposed at the outer biofilm surface, avoiding detection by PRRs [12, 73] and a S. 
aureus-produced matrix of polysaccharide polymers may prevent potential ligands from 
engaging with TLRs [74]. It is highly likely that staphylococcal biofilms produce additional 
factors that contribute to its ability to evade clearance in an immune competent host; 
however, these remain to be completely defined.  
S. aureus is a common etiological agent of chronic debilitating infections, 
especially with the emergence of methicillin-resistant (MRSA) strains that have proven to 
be a therapeutic challenge. S. epidermidis is often overshadowed by MRSA because it 
encodes fewer virulence determinants by comparison; however, S. epidermidis is also a 
frequent cause of medical device-associated biofilm infections [2, 7, 75]. All humans are 
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colonized with S. epidermidis, while S. aureus is found in approximately 30% of 
individuals [76, 77]. Massey et al. predicted that for species with a high level of 
asymptomatic transmission, like S. epidermidis, less virulent strains out-compete virulent 
strains [78]. This would explain why S. epidermidis is equipped with determinants that 
promote persistence, such as immune evasion molecules, rather than toxins that actively 
attack the host. S. epidermidis generally acts as a commensal on the skin of humans, 
but harbors a limited subset of host defense mechanisms to persist in this environment, 
although a more robust defense is needed after penetration of the epithelial barrier [79]. 
Poly-γ-DL-glutamic acid (PGA) is secreted by S. epidermidis to promote growth and 
survival in the high-salt environment of human skin [80], and can form a capsule that 
shelters the bacteria from antimicrobial peptides and neutrophil phagocytosis [81, 82]. 
The cap gene locus drives PGA production and provides resistance to antibacterial 
peptides from human skin and phagocytosis. Cap mutant strains in a mouse catheter 
biofilm infection model were completely cleared [80], suggesting that PGA is critical for 
persistent S. epidermidis biofilm infection.  
S. epidermidis biofilm formation is partially influenced by products from the ica 
operon. Polysaccharide intercellular adhesion (PIA) crosslinks S. epidermidis cells in a 
biofilm [83], protecting bacteria from IgG, AMPs, phagocytosis, and complement [22, 84]. 
C3b and IgG deposition was diminished on biofilms compared to planktonic cells, 
protecting biofilm-associated bacteria from neutrophil killing [84]. Another molecule, 
accumulation-associated protein (Aap) was shown to contribute to S. epidermidis biofilm 
formation under dynamic conditions. Namely, in a rat jugular catheter model of S. 
epidermidis infection, an Aap mutant displayed impaired colonization of the catheter 
surface compared to WT bacteria [85]. However, this required immunosuppression to 
maintain bacteremia and facilitate biofilm formation. Another study demonstrated that 
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macrophage activity was attenuated by S. epidermidis biofilms, in agreement with S. 
aureus biofilms [86]. IFN-γ production from lymphocytes occurs after stimulation by 
activated macrophages and only minimal levels of IFN-γ were produced following 
exposure to biofilm compared to planktonic organisms [87]. S. epidermidis is also 
capable of sensing host immune factors and enhancing defense systems in response to 
these insults [88]. For example, the antimicrobial peptide-sensing system (aps) is 
activated by a range of AMPs and causes the D-alanylation of teichoic acids [89] and 
phospholipid lysylation by the MprF enzyme [90]. MprF decreases the anionic charge at 
the bacterial surface, inhibiting the attraction of cationic AMPs. The effects of MprF 
expression in the context of biofilm immune evasion has not been investigated; however, 
it is reasonable to assume that modifying the charge at the bacterial surface would likely 
increase biofilm dissemination due to weakened attraction to positively charged 
exopolysaccharides (PIA) and proteins. S. epidermidis successfully utilizes a balanced 
system of surface modifications and secreted factors to remain undetected by host 
immune cells ensuring its success as a commensal and potential as an infectious 
pathogen. Further studies of staphylococcal biofilms and the host response to infection 
are needed in order to determine therapeutic targets of the immune system, and combat 
these persistent infections. 
Immune effector cells and their role during staphylococcal biofilm infection 
Macrophages 
Macrophages represent an immediate line of defense against microbial invasion 
because all organs throughout the body harbor a resident macrophage population that is 
an important source of immune signaling molecules [91-93]. Macrophages also have a 
role in regulating tissue homeostasis by removing apoptotic cells and recycling nutrients 
by eliminating waste products from tissues [94-96]. Derived from bone marrow myeloid 
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precursors of the granulocytic-monocytic lineage, monocytes enter the systemic 
circulation and become macrophages after crossing endothelial venules and entering 
tissues [96]. These resident macrophages can be activated by various stimuli through 
their Toll-like and scavenger receptors, and defend the host against invading microbes. 
While known for their phagocytic abilities and production of antimicrobial reactive oxygen 
species (ROS) and reactive nitrogen intermediates (RNI), macrophages are also a major 
source of cytokines and chemokines that are critical for controlling immune cell 
recruitment/activation following bacterial exposure [97, 98]. Several in vivo models of 
staphylococcal biofilms have demonstrated that macrophages [8] and MDSCs [40, 41, 
99] are the main leukocyte infiltrates, while neutrophil recruitment is mainly observed 
during acute infection and rapidly diminishes thereafter.  
The macrophage inflammatory signature has been generally categorized into two 
distinct activation states, namely classically-activated (pro-inflammatory) and 
alternatively-activated (anti-inflammatory). These populations were originally described 
as M1 and M2, respectively, based on their in vitro responses to defined stimuli and 
three different polarization states have since been identified for M2 (i.e. M2a, M2b, and 
M2c) [100-102]. However, it is now apparent that this clear-cut dichotomy does not exist 
in vivo and macrophage activation states are more of a continuum with a mix of M1/M2 
genes often being expressed, driven by the environment and stimuli the cell encounters 
[100]. Therefore, for the purposes of this thesis we will refer to these cells in descriptive 
terms as pro- or anti-inflammatory macrophages. Pro-inflammatory macrophages are a 
major source of pro-inflammatory cytokines (IL-6, TNFα, IL-1β, IFN-γ, IFN-β) and 
ROS/RNI [103], whereas anti-inflammatory macrophages promote a fibrotic response 
and display attenuated microbicidal activity by expressing arginase-1 (Arg-1), IL-4, and 
IL-10. Inducible nitric oxide synthase (iNOS) competes with Arg-1 for the common 
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substrate arginine, which has been attributed to promoting microbicidal activity versus 
wound healing, respectively. S. aureus biofilms have developed mechanisms to alter 
macrophage phenotypes by attenuating iNOS while inducing high Arg-1 expression [12], 
which has been shown to promote collagen formation and fibrosis, hindering biofilm 
clearance [12] (Fig. 1.1.). In addition, further limiting host pro-inflammatory potential with 
the use of MyD88 KO mice resulted in exaggerated fibrosis in a model of S. aureus 
catheter-associated biofilm infection [19]. Indeed, biofilm-associated device infections in 
animal models and humans typically display strong fibrotic responses [99, 104, 105]. 
The fibrotic capsule may physically prevent immune cells from invading the biofilm, mask 
bacterial antigens, and limit antibiotic penetration, perhaps partially accounting for the 
recalcitrance of staphylococcal biofilms to these drugs. Additionally, fibrosis may 
promote dissemination and adhesion of bacteria via adhesion molecules (extracellular 
fibrinogen binding protein, fibronectin-binding proteins) expressed by staphylococci that 
bind proteins associated with the fibrotic response (i.e. collagen, fibronectin).  
Despite the numerous PRRs expressed by host leukocytes and pro-inflammatory 
mediators induced by staphylococci, the host immune response is often not sufficient to 
clear biofilm infections. Macrophages have been shown to invade biofilm structures to 
some extent, however their ability to phagocytose biofilm-associated staphylococci is 
limited, and the majority of invading macrophages are killed in vitro [11, 12]. This failure 
is likely due to the inability of macrophages to physically engulf or opsonize the intact 
biofilm structure, possibly as a result of its size and complex structure. This hypothesis is 
in part supported by evidence of macrophages successfully phagocytosing bacteria from 
mechanically disrupted biofilms [12]. The death of invading macrophages can be 
attributed to S. aureus toxin action (i.e. Hla and LukAB); however, fluctuations in pH, 
oxygenation status, and release of other toxic byproducts from the biofilm may also play 
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a role [106-108]. Even if some macrophages manage to phagocytose bacteria from the 
biofilm structure, it is not sufficient to have a major impact on biofilm survival (Fig. 1.1.). 
Phagocytes possess many bactericidal effector mechanisms such as, vacuole 
acidification, ROS/RNI, cationic molecules, myeloperoxidase, and lysozyme. S. aureus 
has developed resistance to many of these mechanisms. For example, antimicrobial 
peptides (AMPs) are cationic molecules that destroy bacterial cell membranes by 
targeting the lipid bilayer structure [109]. Staphylococci avoid AMP killing by charge 
modification of cell membranes, proteolytic degradation, and AMP binding and 
inactivation [89, 110]. Alanylation of teichoic acids (via the dlt operon) in the bacterial cell 
wall incorporates positively charged residues, allowing for biofilm formation [111], while 
also causing the electrostatic repulsion of AMPs and resistance to neutrophil killing [89]. 
Lysyl-phosphatidylglycerol modifications of teichoic acids via mprF or lysC can also 
confer AMP resistance [90, 112]. Staphylokinase is an exoprotein produced by S. aureus 
that binds plasminogen, inhibits the bactericidal effects of alpha-defensins [113], and 
induces bacterial detachment from mature biofilms [114]. The S. aureus metalloprotease 
aureolysin cleaves and inactivates the AMP LL-37 in the lysosome of macrophages and 
neutrophils, in addition to degrading many other substrates [115]. While its function in 
biofilms has yet to be studied, aureolysin expression is controlled by the agr system 
[116], a major regulator of biofilm formation [117, 118]. 
Lysozyme is another host lysosomal enzyme that damages the bacterial cell wall 
by catalyzing PGN hydrolysis.  Lysozyme resistance in S. aureus is attributed to 
membrane bound O-acetyltransferase (oatA) that modifies N-acetylmuramyl residues in 
PGN, preventing lysozyme binding and degradation [119], and although its role from a 
biofilm perspective has yet to be investigated, its importance in immune evasion remains 
significant. S. aureus has been shown to escape the phagosome and survive 
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intracellularly in neutrophils and macrophages [120, 121]. This is thought to be due, in 
part, to antioxidant production. For example, S. aureus catalase neutralizes hydrogen 
peroxide (H2O2), which is utilized by leukocytes to kill bacteria, and secreted catalase 
from staphylococcal biofilms may prevent H2O2 from permeating the complex structure 
[122]. Molecules expressed on the surface of S. aureus, such as the surface factor 
promoting resistance to oxidative killing (SOK), also confer resistance to ROS [123]. 
Production of superoxide dismutases and methionine sulphoxide reductases allow S. 
aureus to resist oxidative stress [124, 125]. Reactive oxygen species can damage 
proteins by methionine oxidation, and S. aureus expresses a number of different 
enzymes to combat this destruction [126, 127]. Staphylococci also employ manganese 
(Mn2+) homeostasis as a defense mechanism due to Mn2+ itself acting as a superoxide 
dismutase [128]. It is important to note that the expression of many of these genes 
responsible for ROS resistance and the stress response (described further below) are 
upregulated in biofilm compared to planktonic cells [129]. While the agr global regulator 
is the main driver of α-hemolysin and toxin production, the SaeRS global regulator in S. 
aureus also plays a part in regulating α-hemolysin, coagulase, and fibronectin-binding 
protein A [130-132]. Sae expression is activated by hydrogen peroxide and was found to 
reduce human neutrophil ROS production, allowing intracellular survival of the pathogen 
[133-138]. 
Phagocytosed bacteria that have evaded immune clearance may act as a 
reservoir for infection persistence [139]. S. aureus [140], S. epidermidis [141], and S. 
lugdunensis [142] have all demonstrated the ability to invade host cells and persist in a 
semi-dormant state, effectively avoiding exposure to antibiotic therapy [143]. These 
bacteria have numerous mechanisms to promote intracellular survival, providing a 
protective niche for pathogenic organisms. For example, capsule polysaccharide 
25 
 
synthesis was enhanced after phagocytosis [144] and could conceivably limit the 
success of degradative enzymes needed to penetrate the thick capsule. The host 
intracellular environment has also been shown to activate staphylococcal stress 
response genes. The stringent response of staphylococci is composed of two key 
components for the switch to tolerant phenotypes upon environmental stress, namely 
rpoS and the alarmone guanosine tetraphosphate (ppGpp) [145]. Upon amino acid 
deprivation, ppGpp synthesis potentiates the transition to a dormant state by decreasing 
protein synthesis capacity and increasing amino acid biosynthesis [146-149]. The 
stringent response is induced in the biofilm state, as well as after phagocytic uptake by 
neutrophils, allowing for intracellular psm expression, subsequent neutrophil lysis, 
bacterial escape, and survival, having major implications for infection dissemination 
[150].  
In addition to the expression of molecules involved in immune evasion and 
intracellular survival, S. aureus strains also express a number of secreted toxins that kill 
host cells (Fig. 1.1.). Various molecules, such as γ-hemolysin (Hlg), α-hemolysin (Hla), 
and leukocidins, oligomerize and interact with specific receptors on the leukocyte 
surface, producing pores and inducing osmotic lysis [151]. Hlg was found to be 
upregulated after phagocytosis, suggesting it has a role in destroying neutrophils [144]. 
Although the role of Hlg in biofilm immune evasion has not been studied, a role of Hla 
has been defined. Scherr et al. [152] demonstrated cooperation between Hla and the 
bicomponent leukotoxin, LukAB, in inhibiting murine macrophage phagocytosis by S. 
aureus biofilms. Another leukotoxin, β-hemolysin (Hlb), degrades sphingomyelin causing 
lysis of human monocytes and inhibition of IL-8 production from endothelial cells, 
impeding neutrophil transmigration [153]. Hlb has also been shown to form covalent 
homodimers in the presence of eDNA, stimulating biofilm formation [154]. Additional 
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leukocidins of S. aureus (PCL, LukED, LukGH, and LukMF) have been described by 
Naimi et al. [155], Alonzo et al. [156], and Spaan et al. [157], although their specific 
functions in the context of biofilms have yet to be elucidated. The previously mentioned 
sae system as well as agr is responsible for regulating many of these secreted toxins 
and virulence-associated proteins, often increasing expression after leukocyte exposure, 
which contributes to bacterial persistence. Currently, many questions remain regarding 
the role of bacterial-derived factors in altering the host immune response towards one 
that favors biofilm persistence. 
Myeloid-derived suppressor cells (MDSCs) 
Immune responses elicited by staphylococcal biofilms share many similarities 
with tumors, in part, because both display significant infiltration of anti-inflammatory 
macrophages and MDSCs [12, 158, 159]. MDSCs are a heterogeneous population of 
myeloid progenitor cells that are arrested from fully differentiating into mature cells such 
as granulocytes, macrophages, or dendritic cells (DCs) [160-164]. MDSCs can interact 
with a variety of cell types, including T cells, DCs, macrophages, and natural killer cells 
to regulate anti-inflammatory activity and create an immunosuppressive milieu [162, 
165].  It is thought that two signals are required for the differentiation and activation of 
MDSCs. First, MDSC expansion is thought to be induced during infection, tumors, or 
chronic stimulation, in response to cytokines and growth factors, such as G-CSF, GM-
CSF, M-CSF, IL-6, and VEGF [162, 165]. The second signal activates MDSCs, causing 
increased Arg-1, NO, and suppressive cytokine production (i.e. IL-10), which has been 
attributed to pro-inflammatory molecules like IFN-γ, IL-1β, IL-13, TLR ligands, and others 
[162]. In healthy individuals, if the two signals are not present, myeloid progenitor cells 
quickly differentiate and no expansion of the MDSC population occurs [165-168]. 
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However, under inflammatory conditions, such as those created by bacterial infection, 
excessive cytokine production can influence the growth of MDSC populations [161, 167]. 
S. aureus infections have been associated with profound inhibition of T cell 
responses that are not attributed to T regulatory cells [169]. Instead, MDSCs were found 
to have a major role in regulating the immune response to biofilm infection. MDSCs 
inhibit antigen (Ag)-specific and polyclonal T cell activation by robust Arg-1 expression, 
depleting extracellular arginine needed for T cell responses [161, 170-172]. In particular, 
L-arginine regulates the expression of CD3ζ, as well as the cell cycle regulators cyclin 
D3 and cyclin dependent kinase 4 in T cells [165, 173]. Production of ROS by MDSCs 
has also been shown to inhibit CD8 T cell responses to antigens, preventing an effective 
adaptive immune response to invading pathogens [174]. 
A significant MDSC infiltrate is associated with S. aureus biofilms in vivo, and our 
laboratory was the first to demonstrate that MDSCs play an important role in skewing 
monocytes/macrophages towards an anti-inflammatory phenotype during biofilm 
infection [158] (Fig. 1.1.). In addition to Arg-1, MDSCs from S. aureus biofilms displayed 
increased IL-10 expression. IL-10 production by MDSCs induced anti-inflammatory gene 
expression in monocytes, contributing to the persistence of S. aureus orthopedic biofilm 
infections [41] (Fig. 1.1.). IL-12 has also been found to promote MDSC recruitment and 
bacterial persistence [175], indicating a possible target to dampen MDSC infiltrates. 
Attenuating MDSC influx via Ab-mediated depletion at the infection site improved S. 
aureus clearance in a mouse model of orthopedic implant biofilm infection by promoting 
monocyte and macrophage pro-inflammatory activity [158]. These studies have shown 
that IL-12 is critical for MDSC recruitment to the site of infection and that IL-10 is one 




The evolution of immune responses can vary depending on the strength of the 
initial bacterial challenge, which was recently demonstrated for S. aureus biofilm 
formation. Specifically, our recent study [176] took advantage of IL-12 KO mice that 
displayed impaired MDSC recruitment and improved biofilm clearance to uncover an 
inoculum-dependent influence on subsequent immune responsiveness. This study was 
not feasible in WT animals because MDSC infiltrates and biofilm formation are too 
pronounced to discern differences. A low-challenge dose (103 CFU) of S. aureus in IL-12 
KO mice showed reduced cytokine expression, MDSC recruitment, and improved 
bacterial clearance as compared to WT mice. In contrast, a higher-challenge dose (105 
CFU) negated these differences, demonstrating the importance of bacterial inoculum on 
infection outcome. This is an important point, since some animal models utilize a large 
infectious inoculum or introduce implants that are pre-coated with bacteria [177-182]. By 
extension, a higher bacterial inoculum can accelerate biofilm formation and alter the 
immune response, making it difficult to discern underlying pathophysiological 
mechanisms. In a clinical setting, human PJIs result from colonization with low numbers 
of bacteria, which may provide a survival advantage during acute infection because of 
the inability to trigger a strong pro-inflammatory response [176]. As such, maintaining 
infectious doses as low as possible is desirable when attempting to best model human 
disease. In this regard, our recent study demonstrated similar immune infiltrates in 
human PJI tissues compared to the mouse model, revealing the fidelity of low bacterial 
challenge to reliably represent aspects of human disease [176]. The mechanism 
whereby IL-12 regulates MDSC recruitment and biofilm clearance is unknown, since the 
cytokine is best described for its ability to induce Th1 cells and adaptive immunity [183].  
Information pertaining to adaptive immune responses against staphylococcal 
biofilms is sparse compared to what is known regarding innate immune mechanisms. S. 
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aureus is capable of targeting B cell survival and function through staphylococcal protein 
A (Spa). Spa is involved in biofilm formation [184], and can be found on the bacterial 
surface or secreted into the extracellular space where it can associate with Fc and Fab 
domains of immunoglobulins (Igs) [185, 186]. Immunoglobulins are generated against 
bacterial epitopes and allow recognition by macrophages and neutrophils via the Fc 
domain following opsonization. Spa binds IgG in the incorrect orientation for recognition, 
blocking the Fc domain, thereby preventing staphylococcal phagocytosis and 
complement activation via the classical pathway [187-189]. Binding of the Fab domain 
by Spa promotes B cell superantigen activity [190]. Protein A binds the Vh3 region of 
IgM on the surface of B lymphocytes, initiating proliferation and receptor-mediated 
programmed cell death [190]. Together, these mechanisms enact Spa as an effective 
suppressor of adaptive immune responses.  
Just as with B cells, the known roles of T cell responses to biofilm infections are 
limited. Evaluation of human tissues recovered from orthopedic prosthetic surgery 
revealed that T cells were limited in PJIs, whereas tissues from subjects with aseptic 
prosthetic loosening displayed a noticeable T cell population [175]. Additionally, some in 
vivo studies indicate that T cells may play a role in orthopedic implant biofilm infections 
[177]. Inflammatory cytokines representative of Th1 and Th17 responses, as well as 
Th1-dependent antibodies, were found to be upregulated throughout biofilm infection [9]. 
However, it is important to note that these studies utilized implants that were pre-coated 
with bacteria, which likely elicits a distinct inflammatory cascade compared to low 
numbers of bacteria that establish biofilm infections in humans [176]. This could explain 
the disparity in T cell responses observed between laboratories, as other studies have 
shown the T cell infiltrate and contribution to immune response to be negligible [11]. S. 
aureus may promote T cell lysis by expressing δ-hemolysin, a PSM that is regulated by 
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agr-mediated quorum sensing and may be influenced by the biofilm state, since agr 
action has been associated with biofilm dispersal [117, 191, 192]. Staphylococcal 
superantigens activate vast numbers of T cells by their ability to crosslink MHC Class II 
on antigen presenting cells to the T cell receptor, followed by widespread T cell 
apoptosis that effectively prevents memory cell development [193]. S. aureus biofilms 
have been shown to produce superantigens that caused T cell activation and elicited a 
systemic inflammatory response in the absence of systemic infection [194]. This study 
was performed with transgenic mice expressing human MHC Class II (HLA-DR), since 
staphylococcal superantigens are not highly reactive with mouse MHC molecules [195]. 
S. aureus strains also produce a MHC class II analogue protein (Map) that reduces 
lymphocyte proliferation and shifts the immune response to Th2, suppressing Th1-
dependent bacterial clearance [196]. However, the expression and functional impact of 
these molecules in the context of staphylococcal biofilm formation remain to be 
determined. 
Neutrophils 
Neutrophils are a primary line of defense against planktonic staphylococcal 
infections [5, 197, 198]. These phagocytic cells of the innate immune system are often 
called the “first responders” to an infection due to their rapid migration to sites of 
inflammation [197, 199]. However, unlike macrophages, neutrophil inflammatory 
cytokine and chemokine production is limited, and their short lifespan necessitates 
constant recruitment due to rapid cell turnover, making it difficult for these cells to 
combat a persistent biofilm infection. Engagement of PRRs activates pathways critical 
for bacterial phagocytosis and microbicidal activity, which elicit an oxidative burst within 
the phagosome, mediated by NADPH oxidase and iNOS that generate ROS and RNI, 
respectively. Bactericidal activity is augmented following phagosome-lysosome fusion, 
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since the lysosome is rich in proteases, cathepsins, defensins, and other antimicrobial 
effectors, creating an inhospitable environment for bacteria [200]. Despite the extensive 
array of antibacterial mechanisms neutrophils employ to combat infection, pathogens 
have evolved to evade these host-defense strategies through various means. 
Staphylococci utilize several antioxidants to counteract ROS action and survive 
within the phagosome, including alkyl hydroperoxide reductase, staphyloxanthin, 
catalase, and SOK, among others [122-124, 201]. Neutrophils have been shown to 
phagocytose biofilm-associated bacteria but at a reduced level compared to planktonic 
bacteria or immature biofilms [12, 202]. Some of the antioxidants produced by S. aureus 
have been shown to be upregulated in biofilm-associated cells; specifically 
staphyloxanthin, catalase, and superoxide dismutase (SOD) [129], indicating that cells in 
a biofilm are better equipped to deal with stressful conditions upon phagocytosis. In 
addition, S. aureus biofilms do not dramatically alter their transcriptional profiles 
following neutrophil exposure [20] and although neutrophils infiltrate sites of early S. 
aureus biofilm infection [158], this occurs at a time when bacteria are still in a planktonic 
growth state (i.e. day 3 post-infection). Once mature biofilms form, around day 7 based 
on recalcitrance to antibiotic action, neutrophils are rare and are replaced by large 
numbers of MDSCs [158] (Fig. 1.1.). 
The fact that few neutrophils are associated with S. aureus biofilm infections [12] 
could be attributed to the many virulence and immune evasion factors produced by S. 
aureus. In order to reach the biofilm and mediate bacterial clearance, neutrophils must 
adhere to and cross the capillary endothelium. This is accomplished through reciprocal 
interactions between endothelial receptors and ligands on the neutrophil surface. 
Neutrophil chemotaxis and extravasation is thwarted by multiple S. aureus secreted 
factors, such as SSLs, PSMs, chemotaxis inhibitory protein of S. aureus (CHIPS), formyl 
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peptide receptor-like 1 inhibitor (FLIPr), and FLIPr-like proteins [5]. Although these 
virulence determinants have been implicated in circumventing neutrophil recruitment 
during planktonic S. aureus infection, their role in preventing neutrophil influx into 
biofilms remains unknown. If similar mechanisms of action exist, this may be one 
explanation to account for the paucity of neutrophils associated with S. aureus biofilms. 
Nevertheless, a recent study from our laboratory demonstrated that the exogenous 
introduction of neutrophils at the site of S. aureus biofilm infection was not capable of 
preventing biofilm establishment [203], further supporting their ineffectiveness against 
biofilm growth. 
Neutrophils are recruited to sites of infection by chemotactic gradients sensed by 
membrane bound G-protein coupled receptors (GPCRs), such as FPR1-3 and CXCRs 
[204-207]. PSMs interfere with these chemoattractants by binding human formyl peptide 
receptor 2 (FPR2) [208]. N-formyl peptides are found on the surface of S. aureus and 
induce chemotaxis, phagocytosis, and oxidative burst of neutrophils and monocytes 
[209]. CHIPS binds C5a and N-formyl peptide receptors on human leukocytes, 
effectively negating chemoattractant activity and preventing leukocyte recruitment to 
sites of infection [210]. The expression of extracellular adherence protein (Eap) by S. 
aureus binds and blocks ICAM-1, the endothelial receptor needed for leukocyte 
adhesion and diapedesis [211]. FLIPr and FLIPr-like inhibit FPR1 and FPR2, thereby 
evading recognition of secreted PSMs [208, 212, 213], and both FLIPr proteins inhibit 
neutrophil Ca2+ mobilization and actin polymerization [214-216]. Staphopain A, a 
protease secreted by S. aureus during biofilm growth, inhibits neutrophil migration 
toward CXCR2 chemokines by cleavage of their N-terminal domain [215]. It is important 
to note that many virulence factors produced by staphylococci, such as staphylococcal 
complement inhibitor (SCIN), extracellular fibrinogen binding protein (Efb), extracellular 
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complement binding protein (Ecb), and CHIPS, are highly species-specific with activity 
mainly limited to human cells, having little to no apparent effect on leukocytes in animal 
models [217]. Together, CHIPS, FLIPr, and SSLs, inhibit chemoattractant-mediated 
migration, effectively promoting planktonic infection; however, their involvement during 
staphylococcal biofilm formation remains to be determined. 
Just as neutrophils have mechanisms to recognize and destroy invading 
pathogens via PRRs, S. aureus strains can respond and produce a plethora of virulence 
factors to counteract neutrophil function, including hemolysins, leukotoxins, iron 
scavengers, and stress response genes [218]. Phagocytosed staphylococci are capable 
of surviving ROS in phagosomes and causing host cell lysis [219]. Genes involved in 
capsule synthesis, gene regulation, oxidative stress, and virulence have also been 
reported to be up-regulated following neutrophil phagocytosis [144]. Physical and 
electrochemical cell wall properties resist secreted neutrophil defensins and lysozyme, 
while neutralizing enzymes (i.e. catalase) and carotenoid pigment confer resistance to 
ROS [5, 119, 220]. Immediately following phagocytosis, catalase, thioredoxin, 
thioredoxin reductase, SOD, alkyl hydroperoxide reductase, and glutathione peroxidase 
levels have been reported to be upregulated in S. aureus, corresponding with maximal 
neutrophil ROS generation [144]. Genes associated with virulence, including 
plasminogen binding protein, epidermin immunity/lantibiotic proteins, FnBPs, 
staphylocoagulase, clumping factors, γ-hemolysins, and exotoxin 2, can be upregulated 
upon phagocytosis [144].The agr quorum sensing system has been implicated in 
intracellular staphylococcal survival in neutrophils and is responsible for the induction of 
many of the aforementioned virulence factors. The concentration of auto-inducing 
peptide (AIP) required for agr activation can reach critical levels within host cells, 
augmenting PSM expression and ultimately neutrophil lysis [221]. Because neutrophils 
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are targeted by staphylococcal virulence factors rather than undergoing programmed cell 
death, staphylococcal-mediated neutrophil lysis has been associated with necrosis [222-
224]. The potent antimicrobial molecules released from neutrophils into the extracellular 
space can also cause local bystander tissue damage, further impairing bacterial 
clearance [225]. Although many of the neutrophil evasion tactics of staphylococci 
described above have yet to be studied in the context of biofilm infections, they are 
important to discuss in order to have a comprehensive view of staphylococcal 
interactions with the immune system. 
In addition to phagocytosis, neutrophils employ extracellular traps to contain and 
destroy bacteria. Neutrophil extracellular traps (NETs), produced in response to S. 
aureus and other bacterial pathogens, are comprised of extruded DNA, histones, and 
microbicidal effectors [226]. Previously, it was thought that neutrophils underwent cell 
lysis to deploy NETs; however, a novel mechanism of NET formation that does not 
require neutrophil lysis has been reported by Pilsczek et al. [227]. In this model, 
neutrophils actively release intact vesicles filled with nuclear DNA into the extracellular 
space where they rupture and release chromatin. Entrapped bacteria are subject to 
peptidoglycan recognition protein S (PGRPS) and proteases, such as elastase [228]. 
These molecules ensnare bacteria to facilitate neutrophil phagocytosis and subsequent 
killing [229]. However, S. aureus harbors additional virulence mechanisms to subvert 
NETs, including nuclease and adenosine synthase that degrade and convert NET DNA 
to deoxyadenosine, allowing for pathogen escape [230]. Adenosine is a potent 
immunosuppressive molecule normally formed by cells after severe damage, such as 
hypoxic stress, ROS exposure, or cell lysis [231, 232]. Additionally, adenosine 
decreases MHC Class II expression in macrophages and dendritic cells and dampens 
IL-12 production [183]. By extension, staphylococcal enhancement of adenosine 
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production may interfere with T cell effector mechanisms and adaptive immune 
responses in infected hosts [233]. Adenosine triggers anti-inflammatory signaling 
cascades that inhibit neutrophil oxidative burst and degranulation, IL-1 production, and 
increase IL-10 production [234, 235]. Thus, AdsA-mediated synthesis of adenosine 
promotes S. aureus survival within neutrophils, presumably by inhibiting the superoxide 
burst and/or degranulation [233]. Deoxyadenosine (dAdo) triggers the caspase-3-
mediated death of immune cells and macrophage exclusion from abscesses [236]. 
Treatment of human cells with dAdo causes intracellular dATP accumulation, which 
stalls DNA synthesis and triggers monocyte and macrophage apoptosis surrounding 
abscesses [237]. Interestingly, a global transcriptome analysis of S. aureus biofilm 
genes that were altered following macrophage exposure found that thermonuclease 
(Nuc) was one of the most strongly downregulated genes following 1 h of biofilm-
macrophage co-culture [238]. Nuc downregulation is surprising due to the potential anti-
inflammatory advantage of adenosine production by the biofilm and the predicted role of 
Nuc to degrade NETs. This is yet another example that much is still unknown with 
regards to biofilm-immune crosstalk during staphylococcal biofilm infections. 
Osteocytes 
S. aureus is a leading cause of bone and joint infections, such as osteomyelitis 
and PJIs, which can result in approximately 10-20% of bone loss near the infectious 
focus [239]. Implanted biomaterials are susceptible to microbial colonization and biofilm 
formation, favoring the onset of infection [240]. S. aureus has been found to affect at 
least two different cell types found in bone, namely osteoblasts and osteoclasts. 
Osteoclasts are bone matrix-degrading cells generated from the fusion of monocyte 
precursors and share conserved signaling pathways with monocytes and macrophages 
[241], while osteoblasts are derived from mesenchymal stem cells and are responsible 
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for bone formation. To date, staphylococcal interactions with osteoclasts and osteoblasts 
have been investigated using a murine S. aureus osteomyelitis model [242, 243]. Protein 
A, secreted by staphylococci, can bind pre-osteoblastic cells via tumor necrosis factor 
receptor 1 (TNFR1), resulting in osteoblast apoptosis [242-244]. Aside from directly 
preventing bone formation by destroying osteoblasts, S. aureus is also capable of 
altering osteoblast differentiation. Osteoblasts internalize staphylococci by αvβ1 integrin 
interacting with fibronectin binding protein on the bacterial surface. However, after 
internalization, bacteria persist and either induce host cell death or promote the 
secretion of osteoclastic cytokines such as RANK-L, enhancing osteoclastogenesis 
[245]. Osteoclasts are bone-degrading cells, and S. aureus infection of bone marrow-
derived osteoclast precursors induced their differentiation into activated macrophages 
that secrete pro-inflammatory cytokines, enhancing the bone resorption capacity of other 
osteoclasts [246]. Furthermore, infection of mature osteoclasts directly enhanced their 
ability to resorb bone by promoting cellular fusion [246]. The hypoxic nature of healthy 
bone is exacerbated during infection and may explain the incredible persistence of S. 
aureus joint infections. Hypoxic growth of S. aureus resulted in a profound increase in 
quorum sensing-dependent toxin production and cytotoxicity [247]. 
Pro-inflammatory cytokines and biofilm persistence 
A primary research objective of our laboratory is to understand how the host 
innate immune response is altered during biofilm infections with the goal of redirecting 
this response to facilitate bacterial clearance. It is clear that staphylococci evade and 
disrupt many facets of the innate immune response, although biofilm infections still elicit 
the production of a number of pro-inflammatory mediators. Compared to aseptic 
controls, several pro-inflammatory cytokines are elevated in mouse models of S. aureus 
orthopedic implant infection, including IL-12p40, IL-1β, TNF-α, and G-CSF, as well as 
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the chemokines CXCL2, CCL2, CCL3, and CCL5 [40]. Despite the production of pro-
inflammatory cytokines and chemokines, infected individuals are still unable to clear the 
biofilm infection. Instead, the pro-inflammatory response is likely responsible for 
promoting MDSC recruitment and activation, which is supported by our recent study 
where MDSC infiltrates were significantly reduced in IL-12 KO mice, which translated 
into improved biofilm clearance [40]. Recruitment of MDSCs and alternatively activated 
macrophages contribute to the chronicity of the infection [158]. The anti-inflammatory 
cytokine, IL-10, has been shown to have a role in MDSC recruitment [41] and 
interestingly so has the typically pro-inflammatory cytokine IL-12 [40]. Other pro-
inflammatory mediators, such as IL-6, ROS, and cyclooxygenase-2 (COX2), drive MDSC 
activation, inducing the expression of Arg-1 and anti-inflammatory cytokines that drive 
the environment to one that favors bacterial persistence rather than clearance [248]. 
Theoretically, one could overcome the anti-inflammatory environment by eliciting a 
robust pro-inflammatory response that could facilitate bacterial killing. Our approach has 
employed lipopolysaccharide (LPS) treatments administered systemically and locally at 
the site of infection to augment pro-inflammatory activity. 
The response to systemic LPS has been well characterized, and causes the 
production of several pro-inflammatory mediators through activation of the NF-κB 
pathway [249]. Our hypothesis was that LPS activation of peripheral innate immune cells 
would promote their pro-inflammatory properties, which upon invasion would create a 
more hostile environment for the biofilm and promote bacterial clearance. The best laid 
plans of mice and scientists often go awry. Although as expected, systemic LPS 
treatment led to significant increases in systemic cytokine production and enhanced 
leukocyte killing of S. aureus ex vivo, biofilm burdens were increased nearly 2-log 
compared to vehicle treated mice. In addition, preliminary evidence has shown 
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increased expansion of MDSCs in the spleen of LPS treated mice. Collectively, these 
results suggest that systemic LPS elicits a pro-inflammatory cytokine network, which 
subsequently expands and activates MDSCs in the periphery to promote anti-
inflammatory responses. In turn, this hinders innate immune cell recruitment, not only 
preventing biofilm clearance, but actually exacerbating it. Local LPS administration at the 
site of biofilm infection did not display the same phenotype as systemic treatment. 
Specifically, bacterial burdens were similar in local LPS treated and the vehicle control 
group, although the dose of LPS was nearly 10-fold lower than that given systemically, 
so further investigation is necessary. However, if the trends observed to date continue, 
the potential implications for this research are intriguing. Peripheral immune activation 
and subsequent MDSC activation and expansion, may tip the balance towards an 





Figure 1.1. Mechanisms of staphylococcal biofilm immune evasion. Staphylococcal 
biofilms are adept at evading immune recognition and clearance compared to planktonic 
organisms. These biofilms circumvent Toll-like receptor 2 (TLR2) and TLR9, and the 
leukocyte response is dominated by anti-inflammatory macrophages and myeloid-
derived suppressor cells (MDSCs), partially mediated by IL-10 production. Biofilms also 
augment arginase-1 (Arg-1) expression in macrophages and MDSCs, stimulating fibrosis 
and depleting extracellular arginine needed for T cell activation. S. aureus degrades 
NETs via nuclease and adenosine synthase. Phagocytosed S. aureus are resistant to 
ROS via production of several antioxidants, and are capable of intracellular survival and 
host cell lysis. Evasion of B cell adaptive immune responses has been attributed to Spa 
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SodA Neutralizes superoxide production, 
increased expression in biofilms 
















1) Bacterial strains and microbiological techniques 
Bacterial strain 
S. aureus USA300 LAC is a community-associated methicillin-resistant (CA-MRSA) 
strain isolated from a Los Angeles county (LAC) jail inmate with a SSTI and was also 
responsible for the CA-MRSA outbreak of 2002 [265-268]. We received the isolate from 
Dr. Frank DeLeo (National Institute of Allergy and Infectious Diseases Rocky Mountain 
Laboratories, Hamilton, MT) and cured it of its 27 kb LAC-p03 plasmid encoding 
erythromycin (Erm) resistance [269] by screening for spontaneous erythromycin 
sensitivity as previously described and was designated as USA300 LAC 13C. For the 
purposes of this thesis, this wild type strain will be referred to as USA300 LAC.  
Bacterial storage and preparation 
Bacterial strains were stored as glycerol stocks at -80°C, prepared by growing bacteria 
to exponential phase in brain-heart infusion broth (BHI; Fisher Scientific, Pittsburgh, PA) 
followed by centrifugation at 2,400 rpm for 10 min, 4°C. The bacterial pellet was 
resuspended in 1 ml of cold 1X PBS and washed by centrifuging again at 2,400 rpm for 
10 min, 4°C. After discarding the supernatant, the pellet was resuspended in 20% 
glycerol in 1X PBS, and aliquoted into cryovials and stored at -80°C. From the freezer 
stock, a fresh streak plate was prepared for each experiment to avoid mutation of 
bacteria by prolonged storage at 4°C. 
Preparation of bacteria for in vivo experiments 
Overnight cultures were grown by selecting a single bacterial colony from the streak 
plate using a sterile loop and inoculating 25 ml of autoclaved BHI broth in a 250 ml 
baffled flask and incubating at 37°C overnight for 16 h with constant shaking at 250 rpm. 
Aliquots of 1 ml were transferred from the overnight culture into 1.5 ml Eppendorf 
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microcentrifuge tubes and centrifuged at 14,000 rpm, 4°C for 5 min to pellet the bacteria. 
The supernatant was discarded and the pellet was resuspended in 1ml PBS and 
subsequently washed two more times by centrifuging at 14,000 rpm for 5 min, 4°C. The 
washed bacteria were diluted 1:10 in PBS and the number of planktonic bacteria present 
was estimated by measuring the OD (BioMate 3S Spectrophotometer, Thermo Scientific, 
Waltham, MA) at 620 nm. To prepare inoculum for injection, the washed culture was 
diluted in sterile PBS after estimating the CFU/ml of the overnight culture. For example, 
if the overnight culture was estimated at 5.2 x 109 CFU/ml, three subsequent 1:10 
dilutions would follow: 
1:10 dilution = 5.2 x 108 CFU/ml 
1:10 dilution = 5.2 x 107 CFU/ml 
1:10 dilution = 5.2 x 106 CFU/ml 
 
The following equation was then used to determine the amount of diluted culture needed 
to inject 1x103 CFU in 2 µl (5x105 CFU/ml): 
(5.2 x 106 CFU/ml) * x = 5x105 CFU/ml * 1ml 
x = 0.962 ml diluted culture + 0.038 ml PBS  
or 
x = 962 µl diluted culture + 38 µl PBS 
 
The exact concentration of cells/ml in the overnight culture was determined following 
preparation of bacteria for infection by serial diluting the washed culture in triplicate as 
follows: 
10-2 10 µl of the 1ml washed overnight culture into 90 µl PBS 
10-3 10 µl of 10-2 dilution into 90 µl PBS 
10-4 10 µl of 10-3 dilution into 90 µl PBS 
10-5 10 µl of 10-4 dilution into 90 µl PBS 
10-6 10 µl of 10-5 dilution into 90 µl PBS 
 
Bacterial concentration of the inoculum was determined by plating 10 µl of each dilution 
onto blood agar plates, incubating at 37°C overnight. The following day, the number of 
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bacteria was enumerated and plate counts were averaged to identify the actual CFU 
used for infection. 
2) Mouse strains 
C57BL/6 mice (8-10 weeks old) were obtained from Charles River Laboratories 
(Frederick, MD), from which a breeding colony was established. Mice were housed in 
restricted-access rooms equipped with ventilated microisolator cages and maintained at 
21°C under a 12-h light/12-h dark cycle with ad libitum access to water (Hydropac; Lab 
Products, Seaford, DE) and Teklad rodent chow (Harlan, Indianapolis, IN). These 
studies were conducted in strict accordance with the recommendations in the Guide for 
the Care and Use of Laboratory Animals of the U.S. National Institutes of Health. The 
animal use protocol was approved by the Institutional Animal Care and Use Committee 
of the University of Nebraska Medical Center. 
3) Cell culture techniques 
Primary mouse bone marrow-derived MDSC culture 
Adult C57BL/6 WT mice were euthanized with an overdose of inhaled isoflurane 
(Isothesia, VetUS, Dublin, OH) using a euthanasia chamber and cervical dislocation as 
the secondary method of euthanasia. The abdominal surface of each mouse was 
washed with an excess of 70% EtOH to minimize contamination and a subcutaneous 
incision was made near the midline of the abdomen. Skin was separated from the 
peritoneum until the hind limbs were exposed.  Both hind limbs were removed at the hip 
joint and submerged in 1X PBS on ice until excess tissue and muscle were removed 
with Kimwipes. The clean bones were then place in fresh 1X PBS on ice. The following 
steps were performed under aseptic conditions in a biological safety cabinet with sterile 
autoclaved instruments. Both ends of the bones were cut with scissors and bone marrow 
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was flushed with sterile, cold RPMI using a 26-gauge needle into a 50ml conical tube. 
After all bones were flushed, cells were pipetted to disrupt aggregates, filtered through a 
70 μm cell strainer, and centrifuged at 1,200 rpm for 5 min at 4°C. The supernatant was 
aspirated and red blood cells lysed by the addition of 900μl sterile water for 5 s, followed 
by the immediate addition of100μl 10X PBS to prevent the MDSC precursors from 
lysing. Finally, cells were washed with medium, centrifuged, and counted using trypan 
blue (Lonza, Walkersville, Germany) on a hemocytometer. Cells were plated in 175mm2 
tissue culture dishes at a density of 107 cells/plate in 25ml of RPMI-1640 medium 
supplemented with 10% v/v HI FBS, 1% v/v HEPES, 1% v/v L-glutamine, 0.1% v/v 
antibiotic-antimycotic solution, 40 ng/ml G-CSF and 40 ng/ml GM-CSF (both from 
BioLegend). Cells were then incubated for 4 days at 37°C, 5% CO2. The Ly6G+Ly6C+ 
MDSC population was purified from the mixed cell population by FACS and verified to 
possess T cell inhibitory activity. For some experiments, LPS (LPS-EB Ultrapure, 
Invivogen, San Diego, CA) was added at time of cell plating, or 24 h prior to MDSC 
harvest, at final concentrations of 1 ng/ml, 10 ng/ml, or 100 ng/ml. 
4) Mouse model of S. aureus biofilm infection and LPS treatment 
Mouse model of S. aureus orthopedic implant biofilm infection 
To model infectious complications in patients following surgical device placement, a 
mouse model of S. aureus orthopedic implant biofilm infection was used. Age and sex-
matched mice (8-10 weeks old) were anesthetized with a ketamine/xylazine cocktail at 
100 mg/kg and 5 mg/kg, respectively (Hospira, Lake Forest, IL, USA, and Akorn, 
Decatur, IL, USA), and a medial parapatellar arthrotomy was performed with lateral 
displacement of the quadriceps-patella to access the distal femur. A 26-gauge needle 
was used to create a burr hole in the femoral intercondylar notch extending into the 
intramedullary canal, whereupon a precut 0.8 cm long, orthopedic-grade Kirschner wire 
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(0.6 mm diameter, Nitinol (nickel-titanium); Custom Wire Technologies, Port 
Washington, WI, USA) was inserted, leaving approximately 1 mm protruding into the 
joint space. A total of 103 CFU of S. aureus USA300 LAC was inoculated at the exposed 
tip of the titanium implant. In some experiments, control mice received sterile implants 
using an identical procedure. The quadriceps-patellar complex was reduced to the 
midline and the fascia was sutured with 6-0 metric absorbable sutures before the skin of 
the surgical site was closed with 6-0 metric nylon sutures (both from Covidien, 
Mansfield, MA). Immediately following the surgical procedure, animals received 
Buprenex (0.1 mg/kg s.c.; Reckitt Benckiser Health Care, Hull, North Humberside, 
United Kingdom) for pain relief, and were returned to cages under a heat lamp to ensure 
maintenance of core body temperature until fully recovered from anesthesia. Cages 
were labeled with biohazard cards and monitored daily. A second dose of Buprenex was 
administered 24 h after surgery, and after this interval, all mice exhibited normal 
ambulation and no discernable pain behaviors. 
Systemic and local LPS treatments 
Infected mice were treated with 200 µl doses of 12.5 µg LPS systemically via 
intraperitoneal (i.p.) injection, or 5 µg LPS subcutaneously at the site of infection (right 
knee). The appropriate LPS concentrations were prepared by diluting 5mg/ml LPS-EB 
Ultrapure (Invivogen, CA) in 1X PBS immediately prior to injection. Control (vehicle) 
treatment groups received 200 µl of PBS via i.p. injection. All treatment groups were 
dosed at day 5 and day 6 post-infection. Animals were sacrificed at day 7 post-infection 
for quantification of bacterial burdens, as well as Milliplex analysis described below.  
5) Recovery of biofilm infection-associated tissues 




For some experiments, prior to isoflurane exposure, approximately 250 µl of whole 
blood was collected from each mouse and immediately placed in lithium heparin tubes 
(Terumo, Elkton, MD) to prevent coagulation. Animals were sacrificed by overdose of 
inhaled isoflurane, followed by cervical dislocation. For collecting inflamed soft tissue 
surrounding the infected knee joint, the flank and right leg were flooded with 70% EtOH 
and an incision was made in the flank so the skin could be removed to expose the 
infection site and leg. Next, the subcutaneous tissue dorsal to the patellar tendon was 
excised, weighed, and placed in 0.5 ml 1X PBS + 2% FBS on ice. Muscle and tendon 
tissues were excluded from the analysis. The tissue was dissociated with the blunt end 
of a plunger from a 30cc syringe and passed through a 35 µm filter (BD Falcon, 
Bedford, MA). An aliquot of 150 µl was removed for quantitation of bacterial burdens 
and Milliplex analysis of the supernatant. The remaining filtrate was then processed for 
flow cytometry as described below. After removal of the right leg at the hip joint, the 
muscle was removed from the knee joint and femur. The knee joint was separated from 
the femur allowing for removal of the implant, which was extracted from the femur and 
vortexed for 5 min at 1200 rpm in 100 µl PBS to dislodge adherent bacteria. Both the 
knee joint and femur were weighed and placed in 500 µl homogenization buffer before 
homogenization. These tissues were homogenized using two sequential procedures 
owing to their resilient nature: initially a 30 second dispersal using a hand-held 
homogenizer, followed by disruption in a Bullet Blender (Next Advance, Averill Park, 
NY) for 10 minutes, using 100-mm stainless steel beads (0.9–2.0 mm stainless steel 
blend). To determine bacterial colonization, serial 10-fold dilutions of tissue, knee, and 
femur homogenates as well as implant solutions were plated on trypticase soy agar with 
5% sheep blood (Remel Products, Lenexa, KS). Titers are expressed as CFU per gram 
of tissue or per milliliter for titanium implants. Remaining homogenates were centrifuged 
(20,000 x g, 20 min) and frozen at -80˚C for further analysis by Milliplex bead arrays as 
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described below. For some experiments, the spleen, and right kidney were collected to 
determine the degree of splenomegaly or bacterial dissemination as described above. 
Whole blood S. aureus killing assay 
Whole blood killing of S. aureus was used to determine systemic immunocompetence of 
infected mice. Overnight cultures were grown by selecting a single bacterial colony from 
the streak plate using a sterile loop and inoculating 3 ml of autoclaved BHI broth in a 14 
ml round bottom tube (Corning, Reynosa, Mexico) and incubating at 37°C overnight for 
16 h with constant shaking at 250 rpm. An aliquot of 1 ml was transferred from the 
overnight culture into 1.5 ml Eppendorf microcentrifuge tube and centrifuged at 14,000 
rpm, 4°C for 5 min to pellet the bacteria. The supernatant was discarded and the pellet 
was resuspended in 1ml PBS and subsequently washed two more times by centrifuging 
at 14,000 rpm for 5 min, 4°C. The washed bacteria were diluted 1:10 in PBS and the 
number of planktonic bacteria present was estimated by measuring the OD (BioMate 3S 
Spectrophotometer, Thermo Scientific, Waltham, MA) at 620 nm. Washed bacterial 
were diluted to an estimated concentration of 5 x 107 CFU/ml. After collection, 150 µl of 
whole blood was removed from each heparin tube and placed into individual wells of a 
96-well non-tissue culture-treated plate, at which point 3 µl washed bacteria (1.5 x 105 
CFU) was added to each well, such that the final concentration of bacteria was 
estimated to be 106 CFU/ml. At 30 min, 1 h, and 2 h post-inoculation, one 30 µl aliquot 
was removed from each well for bacterial enumeration. After removal of the aliquot, the 
96-well plate was immediately returned to the incubator at 37˚C until the next time point 
occurred. To determine bacterial survival, serial 10-fold dilutions (in 1X PBS) of each 
sample were plated onto blood agar plates, counted the following day, and averaged 




6) Flow cytometry 
Flow cytometry was used to characterize leukocyte infiltrates in inflamed soft tissues 
surrounding orthopedic implants during S. aureus biofilm infection. Animals were 
sacrificed with an overdose of inhaled isoflurane; tissues were excised as previously 
described and placed in 500 µl FACS buffer (2% FBS in PBS) on ice. Tissues were 
dissociated using the rubber end of a plunger from a 30cc syringe, and passed through 
a 35 µm filter (BD Falcon, Bedford, MA). Following removal of an aliquot for bacterial 
quantitation and Milliplex analysis, the filtrate was washed with 1X PBS and the cells 
were centrifuged at 1200 rpm for 5 min, at 4˚C. After discarding supernatant, the cells 
were resuspended and RBCs were lysed using BD Pharm Lyse (BD Biosciences, San 
Diego, CA) per manufacturer instructions. After lysis, cells were washed and 
resuspended in 500 µl PBS followed by incubation in mouse Fc Block (2 µl/sample, BD 
Biosciences, San Diego, CA) for 20 min at 4˚C, to minimize nonspecific antibody (Ab) 
binding. Aliquots of 100 µl were removed from each sample, pooled, and subsequently 
divided equally into compensation and isotype control tubes to identify gating thresholds 
and assess the degree of nonspecific staining, respectively. The remaining 400 µl of 
each sample was split into two tubes and diluted to 500 µl with 1X PBS. Cells were then 
stained with directly-conjugated antibodies for multicolor flow cytometry analysis, which 
included two separate panels to identify innate immune populations or T cells. 
Antibodies in the innate immune cell panel included CD45-APC, Ly6G-PE, Ly6C-
PerCP-Cy5.5, and F4/80-PE-Cy7. Antibodies in the T cell panel included CD3ε APC, 
CD4 Pacific Blue, CD8a FITC, Ly6C PerCP-Cy5.5, and TCR γ/δ PE. All fluorochrome 
conjugated antibodies were purchased from either BD Biosciences or eBioscience. To 
exclude dead cells from analysis, a Live/Dead Fixable Stain Kit (Life Technologies, 
Eugene, OR) was also used, following the manufacturer’s instructions. Analysis was 
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performed using BD FACSDiva software with cells gated on the live CD45+ leukocyte 
population. From this population, MDSCs were gated on the Ly6G+Ly6C+ cell 
population, non-MDSCs were then designated as monocytes (Ly6C+F4/80-), F4/80+ 
monocytes (Ly6C+F4/80+), or macrophages (Ly6C-F4/80+).  
7) Recovery of biofilm-associated leukocytes and in vitro assays 
Cells were collected from the soft tissue surrounding infected knee joints as described 
above, and leukocyte populations were purified by FACS using CD45-APC, Ly6G-PE, 
and Ly6C-PerCP-Cy5.5. CD45+Ly6C+Ly6Ghigh, CD45+Ly6C+Ly6Gintermediate, and 
CD45+Ly6C+Ly6G- cells were classified as MDSC, intermediate, and monocyte 
populations, respectively. The purity of MDSC cell populations was not examined after 
sorting owing to limited cell numbers. However, cytospins and gene expression analysis 
on sorted populations revealed that sorted MDSCs were highly enriched, as they 
displayed nuclear morphologies and characteristic markers consistent with those 
reported for MDSCs in the literature. 
Polyclonal CD4+ proliferation assays 
Naïve CD57BL/6 WT mice were euthanized with an overdose of inhaled isoflurane, and 
their flanks were flooded with 70% EtOH and spleens were isolated from the peritoneal 
cavity and placed into PBS + 10% FBS on ice. Spleens were dissociated using the blunt 
end of a 30cc syringe, and pressed through a 70 µm filter to generate a single cell 
suspension, centrifuged at 1200 rpm for 10 min, 4˚C and RBCs were lysed using BD 
Pharm Lyse (BD Biosciences, San Diego, CA) per the manufacturer’s instructions. After 
RBC lysis, the remaining cells were washed in 1X PBS, and T cells were isolated by 
autoMACS using a CD4+ T cell isolation kit (Miltenyi Biotec, Germany). CD4+ T cells 
collected by autoMACS were immediately labeled with eFluor 670 cell proliferation dye 
(eBioscience) according to the manufacturer’s instructions. For establishing the 
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functional activity of MDSCs and other leukocytes associated with S. aureus orthopedic 
biofilm infections, T cell proliferation assays were performed. Briefly, eFluor 670–
labeled CD4+ T cells were plated at 1.5 x 105 cells/well in a 96-well round bottom plate 
in RPMI 1640 with 10% FBS, supplemented with 100 ng/ml recombinant mouse IL-2 
(Invitrogen, Frederick, MD). FACS-purified CD45+Ly6C+Ly6Ghigh, 
CD45+Ly6C+Ly6Gintermediate, and CD45+Ly6C+Ly6G- cells were added at 1:1 or 1:5 ratios 
to CD4+ T cells subjected to polyclonal stimulation with 4µl/well CD3/CD28 Dynabeads 
(Life Technologies, Oslo, Norway). Controls of labeled T cells only or labeled T cells 
incubated with Dynabeads were also included. Cell co-cultures were incubated at 37˚C 
for 72 h, whereupon the extent of T cell proliferation was determined by flow cytometry 
and supernatants were saved for cytokine evaluation by Milliplex analysis. 
8) MILLIPLEX multi-analyte bead array 
To evaluate a panel of cytokines/chemokines in the milieu of orthopedic implant-
associated infected tissue, knee joint and femur, a custom-designed mouse microbead 
array was used according to the manufacturer’s instructions (MILLIPLEX; Millipore, 
Billerica, MA). This array allows for the simultaneous detection of 19 different 
inflammatory mediators in a single homogenate, and includes: G-CSF (granulocyte 
colony-stimulating factor), GM-CSF (granulocyte macrophage colony-stimulating factor), 
IL-1α, IL-1β, IL-6, IL-7, IL-9, IL-10, IL-12p40, IL-13, IL-17, CCL2 (monocyte 
chemoattractant protein 1, MCP-1), CCL3 (macrophage inflammatory protein 1α, MIP-
1α), CCL5 (regulated upon activated T cell expressed and secreted, RANTES), CXCL2 
(MIP-2), CXCL9 (monokine induced by IFN-γ, MIG), CXCL10 (IFN-induced protein 10, 
IP-10), TNF-α, and VEGF (vascular endothelial growth factor). Results were analyzed 
using a Bio-Plex workstation (Bio-Rad, Hercules, CA) and normalized to the amount of 
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total protein recovered, determined by a bicinchoninic acid assay (BCA, Bio-Rad), to 
correct for differences in tissue sampling size. 
9) Statistical analysis 
Significant differences between experimental groups were determined using an unpaired 
two-tailed Student t test or a one-way ANOVA with Bonferroni's multiple comparison post 














Chapter 3: Systemic pro-inflammatory signaling augments  





S. aureus is a leading cause of nosocomial and community-associated infections, and 
has a propensity to form biofilms on native tissue and artificial surfaces. These infections 
are difficult to treat with antibiotics and evade immune recognition and clearance, placing 
a significant economic burden on the patient and healthcare system. The ineffective 
immune response has been attributed to the skewing of macrophages towards an anti-
inflammatory phenotype and the recruitment of MDSCs. This promotes fibrosis rather 
than bacterial clearance, and biofilm persistence. In an effort to overcome this immune 
evasion, we have used a strong pro-inflammatory stimulus (LPS) to promote the 
infiltration of bactericidal cells into the biofilm. Two modes of LPS delivery were 
examined; namely systemic administration to activate peripheral immune cells and 
promote their recruitment to the biofilm, as well as local LPS treatment in an attempt to 
revert the anti-inflammatory state of resident leukocytes to a pro-inflammatory state. 
Several pro-inflammatory mediators were elevated in the serum following systemic LPS 
administration, which correlated with improved S. aureus killing ex vivo; however 
bacterial titers at the site of biofilm infection were significantly increased by 2-log. This 
was attributed to enhanced suppressive activity of infiltrating MDSCs, and the 
introduction of a Ly6Gint.Ly6C+ population that was also capable of immune suppression. 
These results demonstrate the importance of a pro-inflammatory milieu for promoting 
MDSC expansion and activation, which exacerbates biofilm establishment Therefore, 
methods to augment S. aureus biofilm clearance should proceed with caution to avoid 





The host immune response to S. aureus biofilms is largely categorized as anti-
inflammatory, with macrophages and MDSCs playing a major role in infection outcome. 
Although an early pro-inflammatory response is evident at the site of infection, 
leukocytes are incapable of effectively clearing the biofilm [40]. Many factors are known 
to contribute to this impaired immune response to biofilms, including S. aureus secretion 
of leukocidins, chemotaxis inhibitors, superantigens, and other proteins and molecules 
that interfere with antimicrobial immunity [5, 12, 270]. Aside from staphylococcal-
produced factors, the immune cell infiltrate consists largely of MDSCs, which dampen 
macrophage pro-inflammatory activity and transform the infection site into an anti-
inflammatory environment [40, 158]. MDSCs produce factors that are capable of 
inhibiting T cell responses, as well as several anti-inflammatory cytokines that play a role 
in macrophage polarization[165]. Macrophages can exhibit different activation states, 
depending on the local microenvironment and the signals they receive. For example, a 
pro-inflammatory macrophage has an increased capacity to eliminate bacteria by 
producing cytokines and chemokines to regulate other immune cells as well as ROS and 
RNI production [271, 272]. However, in the case of S. aureus biofilm infections, 
infiltrating macrophages and the overall immune response, are biased towards an anti-
inflammatory state. It is the goal of our laboratory to reprogram this response towards 
one that favors bacterial clearance. 
Lipopolysaccharide is a potent stimulator of innate immunity in a wide variety of 
species. Only 1 to 2 µg is enough to cause a lethal reaction in humans, whereas rabbits 
and mice can survive doses of up to 10 µg and 50 µg, respectively [273-275]. A larger 
LPS dose induces septic shock through the actions of excessive pro-inflammatory 
cytokines, such as TNF-α and IL-1β; however at lower doses, LPS can trigger numerous 
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physiological immunostimulatory effects [276]. Recognition of LPS through TLR4 leads 
to the activation of several NF-κB-mediated factors and the production of pro-
inflammatory mediators [277, 278]. Therefore, we hypothesized that LPS treatment 
would be an attractive approach to reprogram the immune response to an established 
biofilm infection to promote bacterial clearance.  
Patients undergoing joint replacement surgery are at an increased risk of 
developing a biofilm infection, with S. aureus being the most frequent etiological agent 
[279-281]. Our laboratory utilizes a mouse model of post-arthroplasty joint infection that 
mimics PJI and displays evidence of biofilm formation on the infected implant [39, 158, 
282, 283]. Contrary to our prediction, systemic LPS treatment of infected mice promoted 
biofilm growth rather than clearance, which was associated with significant increases in 
numerous pro-inflammatory cytokines, including CCL2, CXCL9, CCL3, CXCL10. 
Likewise, G-CSF, IL-6, and IL-10 expression was also elevated; factors that are known 
to induce MDSC expansion and activation [284-288]. Indeed, MDSC expansion in the 
blood and spleen of LPS treated mice was evident, yet traditional Ly6G+Ly6C+ MDSC 
populations were decreased at the site of biofilm infection, whereas a novel population of 
Ly6intLy6C+ cells was increased. Additionally, the MDSCs recovered from LPS treated 
mice were found to be more suppressive than MDSCs from vehicle treated animals. In 
contrast to what was observed at the site of biofilm infection, bacterial growth in whole 
blood was inhibited with LPS treatment, indicating that the systemic immune response 
remained bactericidal. These results indicate that an attempt to bolster the immune 
response to biofilm infection can lead to opposite effects locally and systemically. 
Specifically, the immune response at the site of infection appears to become more anti-
inflammatory, while the systemic response becomes hyper-inflammatory. Collectively, 
these studies remind us of the complicated interplay dictating the inflammatory response 
57 
 
to S. aureus biofilms, and the need for more research to understand and ultimately 





LPS treatment enhances intrinsic pro-inflammatory cytokine production during S. 
aureus biofilm infection. LPS is the major component of the outer membrane of gram-
negative bacteria and is recognized by the immune system via TLR4 as an indicator of 
bacterial infection, causing a rapid inflammatory response [289-291]. Here we utilized 
LPS administration in a mouse model of S. aureus orthopedic implant-associated biofilm 
infection in an attempt to revert the immune response from an anti-inflammatory to a pro-
inflammatory state. To assess the effects of LPS treatment, we first examined 
inflammatory mediator production in the serum and soft tissue surrounding the joint in 
the mouse model. Aseptic implants elicited transient inflammatory mediator production, 
most likely originating from the trauma generated during the surgical procedure (Fig. 
3.1). In the serum, several pro-inflammatory mediators, including G-CSF, IL-6, CXCL10 
(IP-10), CCL2 (MCP-1), and CXCL9 (MIG) were significantly increased in LPS compared 
to vehicle treated mice (Fig. 3.1). Other cytokines in the serum were also increased 
following LPS treatment, including, GM-CSF, IL-9, CCL3 (MIP-1α), and CXCL2 (MIP-
2α), although these did not reach statistical significance (Fig. 3.1). Unexpectedly, levels 
of the anti-inflammatory cytokine, IL-10, were also increased with LPS treatment, along 
with decreased production of IL-1α and CCL5 (RANTES) (Fig. 3.1). Cytokine production 
was also measured in the tissue surround the implanted device, but was difficult to 
interpret due to a large variation among samples (Fig. 3.2). Collectively, these data 

















Figure 3.1. LPS treatment alters inflammatory mediator production in serum 
during S. aureus orthopedic biofilm infection. Serum collected at day 7 post-infection 
from sterile and infected mice that were treated with vehicle or 12.5 µg LPS via i.p. 
injection at days 5 and 6, whereupon expression of G-CSF, GM-CSF, IL-1α, IL-1β, IL-9, 
IL-6, IL-10, IL-17, CXCL10, CCL2, CXCL9, CCL3, CXCL2, and CCL5 was quantitated by 
Milliplex. Results were normalized to the amount of total protein recovered to correct for 
alterations in tissue sampling size. Results are representative of 5 mice per group, with 
the number of measurable samples labeled as “X/5”. Significant differences are denoted 
by asterisks (*p < 0.05, **p < 0.01, ****p < .0001; one-way ANOVA with Bonferroni’s 












Figure 3.2. LPS treatment alters inflammatory mediator production in tissue 
during S. aureus orthopedic biofilm infection. Tissue homogenates surrounding 
orthopedic implants were prepared at day 7 post-infection from sterile and infected mice 
that were treated with vehicle or 12.5 µg LPS via i.p. injection at days 5 and 6, 
whereupon expression of G-CSF, GM-CSF, IL-1α, IL-1β, IL-9, IL-6, IL-10, IL-12p40, IL-
17, CXCL10, CCL2, CXCL9, CCL3, CXCL2, CCL5, TNF-α, and VEGF was quantitated 
by Milliplex. Results were normalized to the amount of total protein recovered to correct 
for alterations in tissue sampling size. Results are representative of 5 mice per group, 
with the number of measurable samples labeled as “X/5”. Significant differences are 





LPS treatment enhances S. aureus killing by peripheral blood leukocytes ex vivo. 
To determine if LPS treatment promoted the antimicrobial activity of peripheral blood 
leukocytes compared to S. aureus biofilm infected mice alone, whole blood was 
collected and cultured with planktonic S. aureus ex vivo to assess bactericidal activity. 
Using this approach we were able to distinguish differences in the ability of whole blood 
from different treatment groups to kill S. aureus. Blood from all treatment groups resulted 
in reduced bacterial counts after a 30 min incubation (Fig 3.3). In accordance with 
increased cytokine production, the blood of LPS treated mice was more effective at 
killing S. aureus than the vehicle treated animals (all groups harbored S. aureus 
orthopedic implant infection). After 30 and 60 min, only systemic LPS treatment 
displayed improved killing compared to vehicle treated mice; however, after 2 h of 
incubation, blood from both systemic and local LPS administration groups displayed 
enhanced killing ability (Fig 3.3B). These results indicate that LPS treatment creates a 
hostile systemic environment for S. aureus and prevents bacterial persistence in the 





Figure 3.3. LPS treatment enhances S. aureus killing in whole blood. (A) Time-
course of microbicidal ability of whole blood recovered from mice with S. aureus 
orthopedic biofilm infection that received vehicle, local, or systemic LPS treatments (5 
and 12.5 µg, respectively). (B) Bacterial survival in whole blood at 30 min, 1 h, and 2 h. 
All groups were inoculated at a concentration of 106 CFU per mL. Results are expressed 
as Log10 CFU per mL and are representative of 12 mice per group from two independent 
experiments. Significant differences between treatment groups are denoted as *p < 0.05, 





LPS treatment increases S. aureus growth during orthopedic implant biofilm 
infection. Previous work from our laboratory has demonstrated that augmenting pro-
inflammatory activity, specifically in macrophages, is critical for biofilm clearance in vivo 
[203]. Along the same lines, LPS treatment increased production of multiple pro-
inflammatory cytokines, leading to improved clearance of bacteria in the blood ex vivo 
(Fig. 3.1 and 3.3). Despite the elevated pro-inflammatory immune response systemically, 
LPS treatment did not facilitate bacterial clearance at the site of infection, but rather 
promoted biofilm growth (Fig. 3.4). Systemic LPS treatment caused nearly a 2-log 
increase in bacterial burdens in the surrounding tissue after 7 days of infection, while 
local LPS treatment displayed a similar increase in bacterial titers, but to a lesser degree 
(Fig. 3.4). Differences in bacterial burdens among groups in the femur, joint, and implant 
were not significant; however, it was interesting to note that more mice in the LPS-
treated groups had bacterial burdens that were below the limit of detection at these sites 
compared to vehicle-treated mice (Fig. 3.4). Collectively, these results suggest that 
immune activation via LPS treatment can improve antibacterial activity in the peripheral 































































































































































































Figure 3.4. LPS treatment alters S. aureus biofilm burdens. Bacterial burdens 
associated with the knee joint, surrounding soft tissue, femur, and orthopedic implant at 
day 7 post-infection following local or systemic LPS (5 and 12.5 µg, respectively) or 
vehicle treatment. Results are expressed as CFU per mL for orthopedic implants or CFU 
per gram of tissue to correct for differences in tissue sampling size. Results are 
representative of 5-10 mice per group from three independent experiments, for a total of 
20 mice per group. Significant difference between treatment groups are denoted as *p < 




LPS treatment alters immune cell populations in the blood, spleen, and at the site 
of S. aureus biofilm infection. Pro-inflammatory cytokines have been reported to 
recruit and activate MDSCs [162, 285], as well as regulate macrophage and T cell 
activation [40, 292, 293], which could partially explain the exacerbation of infection in 
LPS treated mice. MDSCs are significantly elevated in the S. aureus orthopedic implant 
infection model compared to aseptic implants, and have been shown to be critical factors 
in attenuating innate immune cell influx and biofilm clearance [40, 41, 158]. Based on the 
unexpected disconnect between pro-inflammatory cytokine production and infection 
outcome, we examined differences in immune cell infiltrates of LPS and vehicle treated 
mice. 
 Examination of leukocyte recruitment revealed that LPS only induced significant 
differences in innate immune cell populations in mice with concurrent S. aureus biofilm 
infection and not with aseptic implants. Specifically, LPS treatment had no significant 
effect on MDSC, monocyte, F4/80+ monocyte, or macrophage populations (Fig. 3.5). In 
agreement with previous reports from our laboratory, S. aureus biofilm infection 
increased MDSC recruitment concomitant with reduced monocyte and macrophage 
populations at the site of infection, compared to sterile implants [40, 41, 158] (Fig. 3.5). 
However, LPS treatment reduced Ly6G+Ly6C+ infiltrates that our laboratory has 
demonstrated to be immune suppressive MDSCs [158] (Fig. 3.5A). Specifically, local 
LPS administration resulted in approximately a 20% reduction of MDSCs, while systemic 
LPS treatment reduced the MDSC infiltrate more drastically, by nearly 60% (Fig. 3.5A). 
In contrast, monocyte populations increased with both LPS paradigms, whereas only 
systemic LPS treatment caused a significant increase in macrophage infiltrates (Fig. 
3.5B and D). F4/80+ monocytes were not significantly different across any treatment 
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group (Fig. 3.5C). Distributions of these Ly6G, Ly6C, and F4/80+ cell populations are 
presented in Figure 3.6.  
 Alterations in leukocyte frequencies in the blood and spleen were also examined 
to elucidate the peripheral immune response to S. aureus and effects of LPS. Despite 
the improved killing ability of whole blood following LPS treatment, MDSCs in the blood 
were actually increased (Fig. 3.7A and 3.8). However, the frequency of other pro-
inflammatory leukocyte populations, including monocytes, F4/80+ monocytes, and Ly6C-
F4/80+ cells were also enhanced with LPS treatment (Fig. 3.7B-D and 3.8), perhaps 
compensating for the increase of MDSCs and enhanced S. aureus bactericidal activity. 
Examination of splenic leukocytes revealed an expansion of MDSCs with LPS treatment 
in infected mice (Fig. 3.9A and 3.10), while all other cell populations remained the same 
(Fig. 3.9B-C and 3.10). Previous studies have shown that under proper conditions, such 
as polymicrobial sepsis or in combination with IFN-γ, LPS administration can lead to the 
expansion and activation of MDSCs in the spleen [164, 294]. This expansion could 
account for increased MDSCs in the blood following LPS treatment (Fig. 3.7 and 3.8). At 
face value, these data appear to be contradictory. Namely, MDSC infiltrates are reduced 
in the joint of LPS treated mice, yet bacterial burdens are increased (Fig. 3.5 and 3.4). In 
contrast, MDSCs are increased in the blood of LPS treated mice, but peripheral blood 
leukocytes display improved killing of planktonic S. aureus (Fig. 3.7 and 3.3). Further 
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Figure 3.5. LPS administration alters leukocyte infiltrates during S. aureus 
orthopedic biofilm infection. Implant-associated tissues from sterile and infected mice 
treated with local or systemic LPS (5 and 12.5 µg, respectively) or vehicle were collected 
7 days after implantation of the orthopedic device, and analyzed by flow cytometry. Each 
bar graph represents quantitation of MDSCs (Ly6G+Ly6C+), inflammatory monocytes 
(Ly6G-Ly6C+), F4/80+ monocytes (Ly6C+F4/80+), and macrophages (Ly6C-F4/80+) in 
each treatment group. Results are expressed as a percentage of the total CD45+ 
leukocyte population. Results are representative of 5 mice per group from three 
independent experiments. **p < 0.01, ***p < 0.001, ****p < 0.0001; one-way ANOVA with 







Figure 3.6. LPS administration alters leukocyte infiltrates during S. aureus 
orthopedic biofilm infection. Implant-associated tissues from sterile and infected mice 
treated with local or systemic LPS (5 and 12.5 µg, respectively) or vehicle were collected 
7 days after implantation of the orthopedic device, and analyzed by flow cytometry. 
Representative contour plots of MDSCs (Ly6G+Ly6C+), inflammatory monocytes (Ly6G-
Ly6C+), F4/80+ monocytes (Ly6C+F4/80+), and macrophages (Ly6C-F4/80+) present in 
each treatment group. (A) Sterile implant, vehicle treatment, (B) sterile implant, local 
LPS treatment, (C) sterile implant, systemic LPS treatment, (D) infected implant, vehicle 
treatment, (E) infected implant, local LPS treatment, and (F) infected implant, systemic 



























































































































































































































































































F 4 /8 0
+

































































































L y 6 C
-
F 4 /8 0
+














* * * *
 
Figure 3.7. LPS administration alters peripheral blood leukocyte populations 
during S. aureus orthopedic biofilm infection. Blood from sterile and infected mice 
treated with local or systemic LPS (5 and 12.5 µg, respectively) or vehicle were collected 
7 days after implantation of the orthopedic device, and analyzed by flow cytometry. Each 
bar graph represents quantitation of MDSCs (Ly6G+Ly6C+), monocytes (Ly6G-Ly6C+), 
F4/80+ monocytes (Ly6C+F4/80+), and Ly6C-F4/80+ cells present in each treatment 
group. Results are expressed as a percentage of the total CD45+ leukocyte population. 
Results are representative of 5 mice per group from two independent experiments. *p < 
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; one-way ANOVA with Bonferroni’s multiple 






Figure 3.8. LPS administration alters blood leukocyte populations during S. 
aureus orthopedic biofilm infection. Blood from sterile and infected mice treated with 
local or systemic LPS (5 and 12.5 µg, respectively) or vehicle were collected 7 days after 
implantation of the orthopedic device, and analyzed by flow cytometry. Representative 
contour plots of MDSCs (Ly6G+Ly6C+), monocytes (Ly6G-Ly6C+), F4/80+ monocytes 
(Ly6C+F4/80+), and Ly6C-F4/80+ cells present in each treatment group. (A) Sterile 
implant, vehicle treatment, (B) sterile implant, local LPS treatment, (C) sterile implant, 
systemic LPS treatment, (D) infected implant, vehicle treatment, (E) infected implant, 
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Figure 3.9. LPS administration alters splenic leukocyte populations during S. 
aureus orthopedic biofilm infection. Spleens from sterile and infected mice treated 
with local or systemic LPS (5 and 12.5 µg, respectively) or vehicle were collected 7 days 
after implantation of the orthopedic device, and analyzed by flow cytometry. Each bar 
graph represents quantitation of MDSCs (Ly6G+Ly6C+), monocytes (Ly6G-Ly6C+), 
F4/80+ monocytes (Ly6C+F4/80+), and Ly6C-F4/80+ cells present in each treatment 
group. Results are expressed as a percentage of the total CD45+ leukocyte population. 
Results are representative of 5 mice per group from two independent experiments. *p < 
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; one-way ANOVA with Bonferroni’s multiple 





Figure 3.10. LPS administration alters splenic leukocyte populations during S. 
aureus orthopedic biofilm infection. Spleens from sterile and infected mice treated 
with local or systemic LPS (5 and 12.5 µg, respectively) or vehicle were collected 7 days 
after implantation of the orthopedic device and analyzed by flow cytometry. 
Representative contour plots of MDSCs (Ly6G+Ly6C+), inflammatory monocytes (Ly6G-
Ly6C+), F4/80+ monocytes (Ly6C+F4/80+), and macrophages (Ly6C-F4/80+) present in 
sterile and infected animals of each treatment group. (A) Sterile implant, vehicle 
treatment, (B) sterile implant, local LPS treatment, (C) sterile implant, systemic LPS 
treatment, (D) infected implant, vehicle treatment, (E) infected implant, local LPS 






LPS treatment augments MDSC inhibitory activity. Our results have demonstrated 
that LPS treatment alters MDSC infiltrates into S. aureus biofilm infections, namely 
causing a shift from a predominant Ly6G+Ly6C+ towards a Ly6GlowLy6C+ population, 
which introduced a Ly6GintermediateLy6C+ population (Fig. 3.6, 3.8, and 3.10). We 
hypothesized that Ly6G expression was downregulated in traditional Ly6G+Ly6C+ 
MDSCs following LPS treatment, nevertheless, these cells remained suppressive, 
accounting for the increased biofilm burdens. To determined the immunosuppressive 
nature of each population, Ly6G-Ly6C+ monocytes, Ly6GintLy6C+ Ly6G intermediates, 
and Ly6G+Ly6C+ MDSCs were purified by FACS and co-cultured with CD4+ T cells to 
determine which cell types could suppress T cell proliferation (Fig. 3.11). As expected, 
monocytes from all treatment groups did not inhibit T cell expansion (Fig. 3.12A). Ly6G 
intermediate cells from mice receiving systemic LPS appeared to possess some 
suppressive activity; however, this did not reach statistical significance (Fig. 3.12B). In 
general, MDSCs from LPS treated animals were more suppressive compared to MDSCs 
from the vehicle treatment mice (Fig. 3.12C). Although these differences were relatively 
modest, it is important to note that differences in total numbers of suppressive cells can 
amplify inhibitory activity in vivo. It is possible that by promoting MDSC activation and 
expansion, LPS treatment enhances anti-inflammatory activity at the site of infection, 




   
 
Figure 3.11. FACS purification of different leukocyte populations after S. aureus 
orthopedic biofilm infection. Leukocyte infiltrates associated with S. aureus-infected 
joints were collected by FACS at day 7  based on Ly6G expression. Contour plots of 
sorted monocytes (Ly6G-Ly6C+), Ly6G intermediates (Ly6Gint.Ly6C+), and MDSCs 
(Ly6G+Ly6C+) in each treatment group: vehicle (A), local LPS (B), systemic LPS (C). All 




















































































































































Figure 3.12. Effects of LPS treatment on MDSC T cell suppressive activity. 
Leukocyte infiltrates associated with S. aureus-infected joints were collected by FACS at 
day 7 based on Ly6G expression. Analysis of ex vivo polyclonal CD4+ T cell proliferation 
following a 1:1 co-culture with (A) monocytes (Ly6G-Ly6C+), (B) Ly6G intermediates 
(Ly6Gint.Ly6C+), and (C) MDSCs (Ly6G+Ly6C+) for 72 h. Results are representative of 
one to three replicates. *p < 0.05, **p < 0.01; one-way ANOVA with Bonferroni’s multiple 
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Figure 3.13. Impact of LPS on leukocyte abundance during S. aureus orthopedic 
biofilm infection. Abundance of the FACS purified Ly6G populations that were 
examined for T cell suppressive activity in Figure 3.XX above, including (A) monocytes 
(Ly6G-Ly6C+), (B) Ly6G intermediates (Ly6Gint.Ly6C+), and (C) MDSCs (Ly6G+Ly6C+). 




Transient but not sustained exposure to LPS causes an expansion of bone-
marrow derived MDSCs in vitro. LPS is known to activate mature MDSCs in the 
presence of pro-inflammatory cytokines [294]; however, based on our findings we 
wanted to determine if LPS alone was capable of triggering MDSC expansion. To 
investigate this possibility, bone marrow cells were cultured for 4 days and treated with 
LPS either at the time of plating or the last 24 h prior to cell harvest. During this time, 
media was not changed. Sustained LPS treatment did not significantly affect MDSC 
expansion, even at the highest concentration of LPS examined (Fig. 3.14). Monocyte 
differentiation decreased approximately 20% with the highest LPS concentration; 
however macrophages and F4/80+ monocytes were not significantly altered (Fig. 3.14, 
3.15).  
In contrast, a dose-dependent increase in MDSCs was observed when cells were 
exposed to LPS for the last 24 h, with 100 ng/ml resulting in the greatest expansion (Fig. 
3.16). It is likely that this increase in MDSCs may be attributed, in part, to reduced 
monocytes with increasing LPS concentrations, which are presumably shifting more 
towards an MDSC phenotype, as macrophages and F4/80+ monocytes remain 
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Figure 3.14. LPS treatment for 4 days does not alter bone marrow-derived 
leukocyte populations in vitro. Bone marrow cells were seeded in non-treated tissue 
culture plates with 1, 10, or 100 ng/ml LPS, or PBS as a control. After 3 days, cells were 
treated with 40 ng/ml IL-6, incubated for another 24 h, and stained for flow cytometry. 
Each bar graph represents quantitation of MDSCs (Ly6G+Ly6C+), monocytes (Ly6G-
Ly6C+), F4/80+ monocytes (Ly6C+F4/80+), and macrophages (Ly6C-F4/80+). Results are 
expressed as a percentage of the total CD45+ leukocyte population. Results are 
representative of 9 replicates from three independent experiments. *p < 0.05, one-way 






Figure 3.15. LPS treatment for 4 days does not alter bone marrow-derived 
leukocyte populations in vitro. Bone marrow cells were seeded in non-treated tissue 
culture plates with 1 (B), 10 (C), or 100 (D) ng/ml LPS, or PBS (A) as a control. After 3 
days, cells were treated with 40 ng/ml IL-6, incubated for another 24 h, and stained for 
flow cytometry. Representative contour plots of MDSCs (Ly6G+Ly6C+), monocytes 
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Figure 3.16. LPS treatment for 24 h expands bone marrow-derived MDSCs in vitro. 
Bone marrow cells were seeded in non-treated tissue culture plates and incubated for 3 
days, whereupon cells were treated with 40 ng/ml IL-6 + 1, 10, or 100 ng/ml LPS, or PBS 
as a control. After incubating for another 24 h, cells were collected and stained for flow 
cytometry. Each bar graph represents quantitation of MDSCs (Ly6G+Ly6C+), monocytes 
(Ly6G-Ly6C+), F4/80+ monocytes (Ly6C+F4/80+), and macrophages (Ly6C-F4/80+) in 
each treatment group. Results are expressed as a percentage of the total CD45+ 
leukocyte population. Results are representative of 9 replicates from three independent 
experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; one-way ANOVA with 





Figure 3.17. LPS treatment for 24 h expands bone marrow-derived MDSCs in vitro. 
Bone marrow cells were seeded in non-treated tissue culture plates and incubated for 3 
days, whereupon cells were treated with 40 ng/ml IL-6 + 1 (B), 10 (C), or 100 (D) ng/ml 
LPS, or PBS (A) as a control. After incubating for another 24 h, cells were collected and 
stained for flow cytometry. Representative contour plots of MDSCs (Ly6G+Ly6C+), 
monocytes (Ly6G-Ly6C+), F4/80+ monocytes (Ly6C+F4/80+), and macrophages (Ly6C-



















 The immune response to S. aureus biofilms is largely ineffective, leading to 
chronic infections that require a significant amount of time, money, and antibiotics to 
treat. S. aureus evades and manipulates the host immune response through numerous 
mechanisms, including interference with antibody-mediated opsonization and 
complement activation, resistance to cationic antimicrobial peptides and ROS, 
impairment of phagocyte recruitment, and production of several leukocidins and toxins 
[5, 295]. Biofilm formation further protects the bacteria from antibiotics and host-
mediated killing, making these infections particularly dangerous and difficult to eradicate. 
A major goal of our laboratory is to redirect the immune response to the biofilm to 
promote the recruitment and activation of bactericidal cells, rather than immune 
suppressive cells.  
 Prior studies have shown that S. aureus biofilms polarize macrophages toward 
an anti-inflammatory state and facilitate the preferential recruitment of MDSCs [12, 158]. 
MDSCs are notable for their expression of several immune-suppressive factors, such as 
Arg-1 and IL-10. Arg-1 activity depletes extracellular arginine, causing T cell dysfunction, 
and reduces its availability for iNOS function by macrophages [296]. We predicted that 
the introduction of a potent pro-inflammatory stimulus, specifically LPS, would induce the 
recruitment of leukocytes that were already programmed for bactericidal activity, which 
would aid in S. aureus biofilm clearance. Although LPS treatment did augment systemic 
pro-inflammatory mediator production, including G-CSF, IL-6, CXCL10, CCL2, and 
CXCL9, effects on bacterial clearance was mixed. For example, bacterial burdens were 
increased in the tissue surrounding the infected joint following LPS administration; 
however, more mice cleared the infection from sites distal to the primary infection site, 
such as the femur and deeper joint capsule. These findings suggest that LPS-dependent 
86 
 
activation could be limiting bacterial dissemination from the initial site of infection while 
simultaneously promoting a local microenvironment that augments biofilm growth. As 
further evidence suggesting that LPS treatment may discourage S. aureus 
dissemination, whole blood collected from LPS treated mice displayed improved killing of 
planktonic S. aureus. Collectively, these results suggest that leukocytes that have yet to 
have direct contact with the biofilm are effectively stimulated by LPS; however, the same 
cannot be said for immune cells located at the site of biofilm infection. 
 Although Ly6G+Ly6C+ MDSCs were decreased following LPS treatment, biofilm 
burdens were increased. This appears to be counterintuitive, as previous studies from 
our laboratory have partially ascribed biofilm immune evasion to MDSC activity, since 
Ab-mediated depletion of MDSCs promotes monocyte/macrophage pro-inflammatory 
activity and biofilm clearance [158]. However, it is important to consider that MDSCs are 
a heterogeneous population of immature monocytes and granulocytes that can be 
divided into different subsets based on their differential expression of Ly6C and Ly6G 
[161, 163, 297]. Namely, polymorphonuclear (PMN) and monocytic (M)-MDSCs are 
defined as CD11b+Ly6G+Ly6Clo and CD11b+Ly6G-Ly6Chi, respectively, and in our model 
of S. aureus orthopedic biofilm infection, the most suppressive cell population was found 
to be Ly6G+Ly6C+, highlighting the variable phenotype of these cells depending on 
environmental context [158, 285, 298]. Due to this variability of phenotypic markers, a 
functional assay, specifically the inhibition of T cells, is the gold standard used to define 
MDSCs [299]. Since LPS administration drastically changed the systemic immune 
environment by increasing pro-inflammatory mediator production, it was reasonable to 
predict that the phenotype and function of MDSCs may be significantly altered from what 
our laboratory has defined previously [40, 158, 276]. 
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 Further examination of Ly6G+Ly6C+ infiltrates revealed that although this 
population decreases in number with LPS treatment, it becomes more suppressive than 
in vehicle treated control animals. Additionally, the Ly6GintLy6C+ population is expanded 
by LPS administration, and displays some suppressive activity, although not significantly 
different from the vehicle control. Direct comparison of these cells is difficult due the low 
numbers that can be collected from vehicle treated mice; however, if the suppressive 
potential of Ly6GintLy6C+ cells can be confirmed in future studies their impact could be 
significant considering their abundance in the tissue of LPS treated mice. The expansion 
of this Ly6G-intermediate population combined with the increased suppressive capability 
of the classical MDSC population at the site of infection likely account, in part, for the 
increased biofilm growth in LPS-treated mice. 
 To explain the altered leukocyte infiltrates with LPS treatment, we examined 
cytokine/chemokine profiles in the different treatment groups. Overall, LPS 
administration appears to elicit a generalized upregulation of numerous pro-inflammatory 
factors, with a few exceptions. Specifically, G-CSF, IL-6, CXCL10, CCL2, and CXCL9 
were significantly increased in the serum of LPS-treated mice, while only IL-1α and 
CCL5 were reduced. Although typically considered pro-inflammatory, these cytokines 
can execute multiple functions, where the environmental context dictates the outcome. 
G-CSF and IL-6 are known to be important for MDSC expansion and activation, while 
CCL2 has been linked to MDSC migration [300-302]. Additionally, IL-10 levels were 
increased with LPS treatment; a pleiotropic cytokine that possesses numerous functions. 
In particular, IL-10 skews macrophages towards an anti-inflammatory phenotype and is 
a known product of activated MDSCs [303-305]. Our laboratory has shown that IL-10 
contributes to S. aureus biofilm infection persistence, since IL-10 KO mice displayed 
reduced MDSC influx, increased monocyte and macrophage infiltrates, and improved 
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biofilm clearance compared to WT animals [41]. Overall, this cytokine profile represents 
an environment that is highly favorable for MDSC recruitment and proliferation, via 
CCL2, IL-6, and G-CSF, as well as heightened MDSC activity through increased IL-10 
production. 
 With increasing distance from the primary site of biofilm infection, another 
conundrum emerges. Namely, although MDSC infiltrates increase following systemic 
LPS administration, whole blood from this treatment group displayed improved bacterial 
killing compared to the PBS-treated control group. This result may be explained by the 
increased recruitment of bactericidal effectors, such as monocytes and Ly6C-F4/80+ 
cells. We propose that these cells remain pro-inflammatory and are minimally inhibited 
by surrounding MDSCs, perhaps because the peripherally expanded MDSC population 
is not fully activated, and may not become activated until coming into contact with 
unknown factors in the biofilm milieu. Meanwhile in the blood, phagocytes are 
hyperactivated by LPS treatment, promoting phagocytosis and bactericidal activity, 
which discourages dissemination. As stated earlier, this is further supported by the 
increased incidence of bacterial clearance in the femur and joint of LPS treated mice. 
These results suggest that LPS alone is not enough to activate MDSCs. Our in vitro 
studies revealed that sustained LPS treatment did expand MDSCs from the bone 
marrow. Previously, it has been reported that LPS in combination with IFN-γ could lead 
to enhanced MDSC functions, such as NO release and T cell suppression; however, 
these effects were not observed with single treatments in vitro [294]. Pertinent to the 
experiments described in this report, IL-6 acts as the second signal rather than IFN-γ, 
and concomitant treatment with LPS and IL-6 leads to an increased expansion of 
MDSCs rather than treatment with IL-6 alone. As we continuously discover in 
immunology, timing is everything. Simultaneous exposure of an immune stimulant and 
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MDSC activators leads to a significant effect on cell populations, while staggered 
treatment has little to no effect.  
Collectively, these studies demonstrate that the immune response and function 
of effector cells can be highly variable depending on the environment in the context of S. 
aureus biofilm infections. Attempts to redirect the anti-inflammatory immune response to 
biofilms towards a more pro-inflammatory response had unexpected consequences. 
Namely, hyperactivation of the immune response through LPS treatment may limit 
bacterial dissemination, but worsens localized biofilm infections. The host immune 
system-biofilm interaction is multi-faceted and complex, and there are still many areas 
that remain to be examined. Identifying the factors that control the immune switch from a 
pro-inflammatory to anti-inflammatory state at the site of biofilm infection is an ongoing 





Determine the suppressive capability of peripheral MDSCs 
Although the results and conclusions proposed by this study are intriguing, 
further examination of certain aspects is needed to confirm preliminary observations. In 
particular, MDSCs in the blood of LPS-treated mice are suspected to be inactive, due to 
the bactericidal nature of the other peripheral blood leukocyte populations; however, this 
has yet to be confirmed. The activation state of peripheral blood MDSCs can be 
confirmed by analysis of iNOS and IL-10 expression, as well as their ability to inhibit T 
cell proliferation. MDSCs from the blood and biofilm-infected tissues can be collected by 
FACS, and their suppressive capability compared to confirm that peripheral blood 
MDSCs are not fully activated, and require additional signals to promote an anti-
inflammatory environment. Additionally, MDSC expansion was observed in the spleen of 
LPS treated mice but these cells are expected to be non-suppressive, however this 
remains to be determined. 
 
Utilization of CXCR2 KO mice to examine the effect of LPS on S. aureus 
dissemination 
Bacterial dissemination to systemic organs is typically not observed in wild type 
mice during S. aureus orthopedic biofilm infection; therefore, it is difficult to determine if 
LPS treatments truly prevent bacterial dissemination with the current data. Utilization of 
CXCR2 KO mice could be an acceptable alternative to address this question. CXCR2 is 
responsible for the recognition of multiple chemokines including CXCL1, CXCL3, 
CXCL5, and CXCL7 in mice [306-309], which likely regulate MDSC influx into S. aureus-
infected tissues. Recognizing that there are confounding factors with regards to 
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differences in leukocyte infiltrates, CXCR2 KO mice display significant bacterial 
dissemination to systemic organs due to unchecked bacterial expansion, and may be a 
good model to determine if systemic LPS treatment could thwart biofilm dissemination by 
augmenting the bactericidal activity of peripheral blood leukocytes. 
 
Transcriptional analysis of biofilm-associated MDSCs  
 From the unexpected results of this study, and many others, it is clear that there 
is much left to be learned about the immune response to S. aureus biofilm infections. 
Our laboratory has initiated steps towards gathering more information through the 
transcriptional profiling of biofilm-associated MDSCs and macrophages via RNA 
sequencing (RNA-Seq). Differential expression analysis revealed thousands of genes 
that were up- or down-regulated in both immune cell types when comparing responses 
to planktonic S. aureus vs. biofilms. This data set has confirmed previous results 
published by our laboratory [12, 41, 158], including increased IL-10 production by 
biofilm-associated MDSCs, and decreased expression of several pro-inflammatory 
cytokines from biofilm-associated macrophages. Further mining of this data set will likely 
identify other potential processes regulating immune responses to biofilm infections. The 
use of bioinformatics to perform pathway analysis and gene ontology enrichment 
analysis will highlight interesting genetic targets to explore, and will provide plenty of 
future directions in our laboratory for years to come. Understanding the role of immune 
cells during S. aureus biofilm infections, including the signals required to expand and 
activate MDSCs, as well as the signals that inhibit macrophages and other pro-
inflammatory cells, may allow for the development of novel therapeutic targets that will 
improve the immune response and allow the host to clear these infections with minimal 
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